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1.1 Bacillary dysentery – Shigellosis 
Bacillary dysentery, an acute inflammatory bowel disease, is caused by 
enteroinvasive bacteria of the genus Shigella. After oral uptake the bacteria 
reach the colon, where they have the capacity to invade the colonic and rectal 
epithelium in humans, thereby causing the acute mucosal inflammation that 
characterises the disease. This destructive recto-colitis is responsible for the 
dysenteric symptoms [1].  
Shigellosis is spread all-over the world, even though only 1.5 million of the 
165.7 million annual cases occur in industrialised countries. The vast 
majority takes place in developing countries, often epidemically, with a death 
rate of 1.1 million p.a.. Shigellosis is mainly a disease of impoverished 
people which in about 69 % (112.6 million) of all cases and 61 % (660.000) of 
all fatalities affects children between the ages of one and five years [2]. 
Shigellae classification 
Shigellae are GRAM-negative, nonsporulating, facultative anaerobic bacilli, 
belonging to the family of Enterobacteriaceae. Genetic analysis revealed that 
Shigella belongs to the core of Escherichia coli strains [3]. There are four 
‘species’ and a varying number of serotypes of Shigella [1,2]: 
• Shigella dysenteriae (16 serotypes), only rarely observed in 
industrialised countries (1 %). S. dysenteriae subtype 1 (“Shiga 
bacillus”) accounts for brisk and deadly epidemics in the poorest 
populations, especially in South Asia and sub-Saharan Africa. This 
subtype produces a potent cytotoxin (Shiga toxin), that is capable to 
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induce severe inflammations, including kidney, brain, and red blood 
cell damages [4]. 
• Shigella flexneri (6 serotypes), the most abundant species worldwide, 
dominating in developing countries with 55 – 85 % (industrialised 
countries: 16 %). 
• Shigella sonnei (1 serotype), the most abundant species in 
industrialised countries (77 %). 
• Shigella boydii (8 serotypes), less common (6 %) and almost equally 
distributed all over the world. 
1.2 Pathogenesis by Shigellae 
Shigella is a highly contagious microorganism. As few as 10 - 100 bacteria 
can cause the disease in adults. Bacterial dysentery remains essentially 
limited to the intestinal mucosa, where Shigellae are capable to invade and 
colonise the colon epithelium [1]. 
The invasion into epithelial cells does not occur through the apical side of 
the cells, but - after a passage of the colon epithelium’s tight junctions e.g. 
via Membranous epithelial cells (M cells), (Figure 2.3, p. 4) [5] - from the 
basal side (Figure 2.5, p. 4) [6,7]. 
M cells, specialised to transport antigens (bacteria, etc.) through the colon 
epithelium, present them to associated macrophages. Shigellae have the 
unusual capacity to enter macrophages without damage. After phagocytic 
uptake, they escape from the phagosome and induce apoptosis of the 




Invasive Shigellae induce massive reorganisation of the subcortical 
cytoskeletal network causing the formation of a macropinocytic vacuole, 
followed by the entry into the epithelial cells and quick lysis of the endocytic 
vacuole [8] (Figure 2.6). Escape into the host cytoplasm is followed by an 
actin-dependent motility process [9]. Once inside the epithelial cells, 
Shigellae propagate and spread to adjacent cells (Figure 1a; Figure 2.6, p. 4) 
– well protected from immune cells. Infected epithelial cells attract 
macrophages and polymorphonuclear leucocytes (PMN) from subepithelial 
tissues. The latter disrupt the integrity of the epithelial barrier and facilitate 
further Shigella invasion from the colon (Figure 2.2 and .7, p. 4).  
Figure 1: Intra- and intercellular spread. 
a) Shigellae with actin tails are coloured red1. b) IcsA / N-WASP / ARP2/3 mediated 
intracellular mobility of Shigella. G-actin molecules are indicated by brown spheres, 
F-actin by brown filaments. 
  
In summary, the invasive phenotype of Shigellae results in rupture, invasion 
and destruction of its various cellular targets and finally the mucosal 
barrier [8,10]. Nevertheless, in contrast to macrophages, PMN are able to kill 
Shigellae inside their phagosomes and eventually cope with the infection [7]. 
____________________________________________________________ 





Figure 2: Pathogenesis of S. flexneri [7].  
Lumenal bacteria invade the colonic epithelial layer by three known mechanisms. 
1. S. flexneri can manipulate the tight junction proteins expressed by epithelial cells, 
allowing paracellular movement of bacteria into the sub-mucosa. 
2. Polymorphonuclear leucocytes (PMN) cells recruited by IL-8 and IL-1β produced in 
response to S. flexneri invasion create gaps between epithelial cells, through which 
S. flexneri can transmigrate into the sub-mucosa. 
3. Endocytic M cells transcytose bacteria, releasing them into an intraepithelial pocket 
filled with B and T lymphocytes and macrophages. 
4. Macrophages phagocytose the bacteria. S. flexneri escapes the phagosome and 
induces the macrophage to undergo apoptosis. The apoptotic macrophage releases 
IL-1β. 
5. Submucosal S. flexneri contact the basolateral membrane of epithelial cells, activating 
secretion of proteins through their type III secretion system. Proteins chaperoned in the 
cytosol of S. flexneri are secreted into the epithelial cell’s cytoplasm through a pore 
formed by IpaB and IpaC. IpaC polymerises actin, IpgD dissociates the plasma 
membrane from the actin cytoskeleton, VirA destabilises microtubules and IpaA forms a 
complex with vinculin, depolymerising actin. This creates cell surface extensions which 
form around the bacterium, driving the epithelial cell to take up S. flexneri into a 
vacuole. 
6. IpaB and IpaC lyse the vacuole, releasing S. flexneri into the epithelial cell’s 
cytoplasm. The S. flexneri protein, IcsA is displayed on only one pole of the bacterium, 
creating a polymerised actin tail behind the bacterium. This propels S. flexneri through 
the cytoplasm until it contacts the plasma membrane. The force of the contact creates a 
protrusion into the neighbouring epithelial cell. Both membranes are lysed by IpaB and 
IpaC, releasing S. flexneri into the neighbouring epithelial cell. 
7. Intracellular S. flexneri induces the epithelial cell to release IL-8. IL-8 and the IL-1β 
released from apopotic macrophages are chemotactic to PMN cells (represented by 
dotted arrows), attracting and inducing them to migrate through the epithelial layer to 






1.3 Molecular basis of the Shigella invasion mechanism 
In Shigella, a 220 kb virulence plasmid encodes most of the genes required 
to express the key steps of the invasive phenotype, enabling cell entry, 
intracellular mobility, cell spreading and induction of apoptosis [11,12]. The 
ipa/mxi-spa locus, a 30 kb region on the virulence plasmid, is necessary and 
sufficient to cause entry into epithelial cells via macropinocytosis [8]. The 
virulence factors encoded by this locus facilitate reprogramming of the 
cellular machinery of epithelial as well as immune cells by activating innate 
transport and signalling pathways [13,14]. 
Figure 3: Entrance structure during Shigella invasion.  
Electron microscope image2. 
 
Upon contact with the basolateral side of an epithelial cell, the type III 
secretion apparatus (TTS), a macromolecular structure containing a needle 
protruding from the bacterial surface [15], delivers Shigella effector proteins 
straight from the bacterial cytoplasm into the cytoplasm of the host cell 





by the virulence factors IpaB and IpaC [11] (Figure 2.5, p. 4). In addition, IpaC 
activates an Src tyrosine kinase and thus a signalling cascade within the host 
cell, causing actin dependent filopodia and lamellipodia formation, and 
leading to a macropinocytotic uptake of the bacterium [16] (Figure 3). These 
events result from a multilateral cross-talk between Shigella and host cell 
signaling pathways which regulate the cytoskeleton, essentially by causing 
actin nucleation and polymerisation at the eukaryotic cell membrane [14].  
Once internalised, the macropinocytotic vacuole is quickly lysed by the 
bacterium. Thereby it is released into the host cell cytoplasm. The bacterium 
assembles an F-actin comet at one of its poles enabling mobility within the 
host cell [17] (Figure 2.6, p. 4), and causing a very efficient process of intra-/ 
intercellular colonisation. This intra-/intercellular spread is a crucial step in 
the virulence of Shigella and is driven by the outer membrane protein IcsA 
(VirG). This protein is accumulated at the old pole of the bacterial surface and 
binds to the host cell proteins N-WASP and ARP2/3 leading to a 
polymerisation of actin, and pushing the bacterium forward inside the host 
cell [18,19] (Figure 1b, p. 3; Figure 2.6, p. 4).  
The described virulence factors are only the most prominent ones among a 
vast set of further virulence factors involved in the generation of 
pathogenicity. Below, several pathogenicity factors were selected for a more 
detailed description of functions. 
1.3.1 Pathogenicity factor IpaA, its chaperone Spa15 and the host cell 
protein Vinculin 
Prerequisite for invasion is the TTS mediated translocation of several Shigella 
effector proteins, particularly Ipa (“invasion plasmid encoded antigen”) 
proteins, to the host cytoplasm [11] (Figure 2.5, p. 4). Among them, IpaA is 
involved in the maturation of the entry focus [9]. Deletion of its gene does 
not eliminate the entry capacity, but induces significant attenuation [1].  
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Expression of the ipaA gene occurs independently of the activity of the TTS. 
Within the bacteria, IpaA is stored in association with the chaperone Spa15 to 
maintain its secretion-competent state. In the absence of Spa15, IpaA is 
thought to form premature soluble complexes in the bacterial cytoplasm, 
preventing IpaA secretion [20]. The crystal structure of dimeric Spa15 has 
been solved at a resolution of 1.8 Å [21].  
Figure 4: Effect of IpaA on the cytoskeletal rearrangements of the enty focus [9]. 
In ipaA- strains of Shigella, uncontrolled polymerisation of actin within the host cell 
leads to the formation of protrusions, pushing the bacteria away from the cellular 
surface and thus, hampering inavsion. In contrast, in wild-type Shigella, cell extensions 
are not formed in the contact area between bacterium and host cell, promoting an 
efficient uptake of the bacterium by the host cell. 
 
Cytoskeletal structures are the targets for Shigella entry associated proteins 
like IpaA. To promote a fully functional entry focus, besides the induction of 
the massive cytoskeletal extensions described above, a control by IpaA is 
required. If uncontrolled, the formation of these gigantic cell extensions 
would tend to push the bacterial body away (Figure 4). Actin polymerisation 
in the contact region of the bacterium and the host cell is avoided by a 
binding of IpaA to the N-terminal head domain of Vinculin [22]. This 
cytoskeleton-associated protein orchestrates the formation of cell adherence 
plaques within the host cell, leading to a depolymerisation of available 
F-actin from adjacent cytoskeletal elements. Thus, a pseudo-adherence 
plaque is formed [9]. In combination with the cytoskeletal extensions 
surrounding the bacterial body, a structure is formed that is productive to 
penetrate. Mutants that do not produce IpaA enter epithelial cells with much 
lower efficiency than their wild-type counterpart, whereas they induce entry 
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foci that are larger and much longer lasting than those induced by the wild-
type strain (Figure 4) [22]. Entry foci induced by ipaA mutants show massive 
and persistent actin polymerisation, but fail to form the pseudo-adherence 
plaque that is required for the generation of an endocytic vacuole. Binding of 
IpaA to the N-terminal head domain of Vinculin activates the dormant form 
of Vinculin and induces its opening, thus revealing a functional actin binding 
site that participates in the bundling process in its C-terminal portion. In 
addition, this interaction also results in actin depolymerisation (Figure 5). 
Figure 5: IpaA Vinculin interaction. 
Binding of IpaA to the head domain of the host cell protein Vinculin induces opening of 
Vinculin and F-actin depolymerisation. G-actin molecules are indicated by brown 
spheres, F-actin by brown filaments. 
 
1.3.2 Pathogenicity factor IpgD and its chaperone IpgE 
Another pathogenicity factor involved in the maturation of the entry focus is 
IpgD [23]. Deletion of its gene also does not eliminate the entry capacity of 
the mutants, but significant reduction of invasion events has been 
observed [1]. 
Like IpaA, IpgD is produced independently of TTS activity. Within the 
bacterial cytoplasm, IpgD is stored in association with its specific chaperone 
IpgE [23]. IpgE is necessary and sufficient for the stability of IpgD within the 
cytoplasm. When used to infect tissue culture cells, ipgD as well as ipgE 
mutants elicit entry structures that have a different morphology compared 
with those produced by the wild-type strain [23]. In particular, actin 
rearrangements induced upon contact of bacteria with epithelial cells are 
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altered. The mutants provoke fewer actin rearrangements and less 
membrane ruffling on the cell surface [23]. 
Phosphoinositides play a central role in the control of several cellular events 
including actin cytoskeleton organisation. IpgD is translocated into the host 
cell cytoplasm and acts as a potent inositol-4-phosphatase that specifically 
dephosphorylates phosphatidylinositol-4,5-bisphosphate [PtdIns-(4,5)P2] 
leading to the accumulation of phosphatidylinositol-5-monophosphate 
[PtdIns(5)P]. This transformation of PtdIns(4,5)P2 into PtdIns(5)P by IpgD is 
responsible for dramatic morphological changes of the host cell, leading to a 
decrease in membrane tether force associated with membrane blebbing and 
actin filament remodelling, promoting membrane ruffling at the entry site 
(Figure 2.5, p. 4). Although IpgD is not absolutely required for entry of 
bacteria into cultured cells, it is implicated in entry focus formation [23-25]. 
After secretion, IpgD is thought to form a complex with IpaA within the host 
cell [23]. 
1.3.3 Pathogenicity factor OspD1 
Transcription of several effector genes is regulated by TTS activity which is 
mediated by the transcriptional activator MxiE as well as by its co-activator 
IpgC. OspD1 was identified to negatively control expression of these genes 
regulated by secretion activity. OspD1 associates with the chaperone Spa15 
and the activator MxiE and acts as an anti-activator until it is secreted. The 
TTS activity is induced upon contact of bacteria with host cells. After 
secretion of OspD1, it cannot longer act as an antiactivator within the 
bacterial cell which ultimately leads to the transcription of MxiE dependent 
effector genes [26,27]. 
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1.3.4 Pathogenicity factor IpgB2 
Because of their ubiquitous role in cell biology, Ras-like small G proteins are 
a common target for virulence factors secreted by bacterial pathogens [30]. 
There are well over 100 eukaryotic small G proteins that regulate a myriad of 
cellular processes including growth, differentiation, membrane trafficking, 
cytoskeletal organisation, and nuclear import. Several key features of small G 
proteins allow them to perform these essential functions. First, they act as 
molecular switches cycling between GTP bound (active) and GDP bound 
(inactive) conformations. Second, most small G proteins are post-
translationally modified. The addition of isoprenoid lipid moieties allows 
them to associate with specific subcellular compartments. Third, they 
transmit signaling events in a GTP-dependent manner by activating and/or 
recruiting downstream target proteins to their sites of action.  
IpgB2 subverts host cell signal transduction cascades by mimicking the 
signaling properties of Ras-like GTPases. It stimulates cellular responses 
analogous to GTP-active RhoA, a Ras-related GTP binding protein that 
induces actin stress fiber assembly. IpgB2 neither binds guanine nucleotides 
nor does it show any sequence similarity corresponding to the conserved 
GTPase domain, suggesting that it is a functional but not a structural mimic. 
However, the activity of IpgB2 is dependent on an invariant WxxxE motif 
found in numerous effectors as targeting sequence. Although the bacterial 
protein lacks many of the biochemical attributes of GTPases, it induces actin 
cytoskeletal dynamics in the host cell by stimulating common signaling 
pathways [31]. 
1.3.5 Pathogenicity factor VirF 
The expression of virulence genes is organised hierarchically [32]. Expression 
of a plasmid encoded key transcription activator for virulence gene 
expression, namely virF, directly activates the transcription of virulence factor 
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genes like icsA and of virB. The virB gene product then activates the 
transcription of the mxi/spa- and ipa genes. Thus, VirF is in the centre of 
pathogenicity regulation. The amount of VirF depends on various 
environmental factors, such as pH, osmolarity, temperature and nutrition 
factors. Below 30° C Shigella is not virulent. The virF gene transcription is 
fully activated at 37° C, pH 7.4, physiological osmolarity and in the presence 
of free amino acids (arginine / methionine). Transcription factors encoded by 
the bacterial chromosome with expression sensitive to these environmental 
factors control virF expression [32-34]. Apart from this ‘classical’ regulation, 
the VirF level obviously also depends on an accurate translational 
machinery [34]. Efficient translation of virF mRNA at the ribosome requires 
the presence of modified tRNA molecules. Modification of tRNA bases is very 
common in nature [35]. Two modifications were demonstrated to exhibit 
major influence on the virF mRNA translational speed. In specific tRNA 
molecules the hyper-modified bases queuine in position 34, and 
2-methylthio-N 6-isopentenyladenine in position 37 have to be present. 
Shigella mutants lacking one of these modifications show significantly 
reduced virulence, approved by mutational studies where gene knock-out in 
the tRNA modification pathway resulted in the absence of these 
modifications [36]. 
1.4 tRNA guanine transglycosylase, the gene product of vacC is a 
target for structure-based drug design 
The Shigella vacC gene product, a tRNA guanine transglycosylase (TGT), 
catalyses the incorporation of a queuine precursor into tRNA at position 34, 
the anticodon ‘wobble position’. Mutation of the vacC gene reduces both, the 
VirF level as well as the haemolytic activity to 50 – 60 % of the wild-
type [34,37]. Thus, tRNA modifying enzymes represent promising targets for 
the development of antibiotics. Inhibition of such specific tRNA modification 
steps should result in significantly reduced virulence of Shigella. A crystal 
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structure of the structurally very similar Zymomonas mobilis TGT is 
available [38]. This TGT is employed for structure-based drug design [39-
44].  
tRNA maturation involves a series of post-transcriptional processing steps 
resulting in fully functional tRNA molecules. Among these maturation steps 
nucleoside modification is the most remarkable one. Modifications within or 
around the anticodon are proposed to fine-tune translational speed and 
fidelity or to influence the occurence of frame-shifting events. Nevertheless, 
the present understanding is still rudimentary [45,46]. E.g. only very recently, 
a putative second function of the vacC gene product has been identified. 
E. coli  TGT was found to be able to recognise the virF mRNA and perform 
the site-specific modification of a single base. Thus, TGT has been discussed 
to modulate the VirF translation by a second mechanism, involving a putative 
riboswitch consisting of the VirF encoding mRNA. A UGU sequence that is 
specifically recognised by TGTs was identified, exhibiting adjacent sequences 
(nucleotides 410 – 433 of the virF mRNA) that enable the formation of a 
hairpin structure, similar to the anticodon stemloop of tRNAs [47]. 
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1.5 Aims of the project 
1.5.1 Pathogenicity factors IpaA, IpgE, IpgB2 and OspD1 
The roles of many S. flexneri  virulence genes have been studied in a variety 
of cell culture experiments such as invasion assays and plaque assays or 
through the use of in vivo  animal models [7]. For the present study, the 
following pathogenicity factors were selected for further analyses, especially 
concerning the determination of their three dimensional structures: IpaA, 
IpgE, IpgB2, and OspD1. Therefore, several preceding procedures have to be 
established, such as cloning and overexpression of the selected genes, 
protein purification protocols, as well as high throughput screening of 
crystallisation conditions. Hereafter, the determination of crystal structures 
of single, or complexed pathogenicity factors should be possible.  
Research on S. flexneri virulence factors, including structure analyses, will 
yield further understanding of the molecular basis of S. flexneri mediated 
invasion and destruction of the intestinal mucosa, as well as the role of the 
host’s subsequent innate responses. A comprehensive understanding of 
S. flexneri ’s disease-causing mechanisms at the molecular level is essential 
to develop innovative antipathogenicity molecules against this disease. 
1.5.2 Substrate selectivity and specificity study of tRNA guanine 
transglycosylases of the three domains of life, based on a 
Zymomonas mobilis TGT model system 
Z. mobilis TGT is an established target for structure-based drug design [39-
44]. Nevertheless, TGTs are evolutionary ancient enzymes, present in all 
three domains of life. The catalytic mechanism is thought to be highly 
conserved, even if the enzymes exhibit different in vivo  substrates in a 
domain-specific manner. In vitro, however, ‘foreign’ substrates are as well 
Introduction 15 
 
accepted by some of the TGTs. While archeal TGTs are highly selective and 
accept only guanine and the actual substrate preQ0, bacterial TGTs are able 
to incorporate besides the natural substrate preQ1 also guanine and preQ0. 
Eukaryotic TGTs are considered as the most unselective enzymes in this 
context (Table 1). Thus, to be able to specifically inhibit bacterial TGT, it is of 
high importance to study the selectivity and specificity determining features 
of these enzymes. Z. mobilis TGT was selected to serve as a model system to 
analyse these features in a mutational study. 
Table 1: In vivo and in vitro substrates of TGTs of the three domains [42]. 
X: In vivo substrate; (X): Accepted as a substrate in vitro, -: Not accepted as a substrate. 
    
TGT 
Exchanged 
base guanine preQ0 preQ1 queuine 
Archaeal G15 (X) X - - 
Bacterial G34 (X) (X) X - 
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2 Selected Shigella Pathogenicity Factors 
In cooperation with Johannes Schulze Wischeler [1] and Christian 
Hasewinkel [2] the pathogenicity factor genes ipaA, spa15, ipgB2, ospD1, 
and ipgE were cloned into different plasmid vectors. For some of the 
pathogenicity factors it is reported that the first 20 N-terminal amino acids 
serve as a signal peptide sequence for TTS secretion or could have a 
disadvantageous influence on protein solubility due to high hydro-
phobicity [3-5]. Therefore, for some of the selected genes, the first 60 bp 
were deleted, leading to shortened versions. In order to find suitable 
expression systems, several different variants were created. Plasmid 
constructs leading to the production of tagless, GST-, His6- or Strep-tagged 
proteins as well as full length and shortened versions were cloned. In 
addition, it is known that the presence of specific chaperones takes influence 
on the solubility and stability of these proteins [6-8]. Thus, also co-
expression vectors were used. The chaperone Spa15 has been identified to 
stabilise IpaA [7], and OspD1 [8], while IpgE is known to specifically stabilise 
IpgD [6]. Additionally, effects of Spa15 on IpgB2 solubility were also 
analysed. In case of IpaA it was assumed, that co-expression with other 
interaction partners could avoid aggregation of this pathogenicity factor. 
Vinculin, the host interaction partner of IpaA, mainly binds with its head 
domain to this bacterial effector [9,10]. Hence, also the part of the human 
vinculin gene corresponding to the head domain (vinc_hd ) was cloned into 
the co-expression vector with ipaA. 
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2.1 Cloning and Expression of ipaA, spa15, vinc_hd, ipgB2, 
ospD1, ipgE 
The following pathogenicity factor genes were amplified via PCR from the 
Shigella virulence plasmid pCP301 [11] using the primers listed in Table 4 
(p. 33): ipaA, spa15, ipgB2, ospD1, ipgE [1,2]. The plasmid vector pCMV-
SPORT6 containing the human vinculin gene was purchased from the 
Deutsche Ressourcenzentrum für Genomforschung GmbH. The first 
2,550 bps of the vinculin gene encoding the head domain were as well 
amplified via PCR using the primers listed in Table 4 (p. 33). Subsequently, all 
PCR products were digested with the corresponding restriction enzymes 
listed in Table 2 (p. 23), purified via minispin colums (peQlab) and cloned 
into the plasmid vectors pPR-IBA2, pET-Duet-1, pGEx-6p-mod [12]. The 
resulting constructs are listed in Table 2 (p. 23). 
In case of ipgE first expression experiments had already shown that the 
expression level is very low, possibly due to rare codon usage. Therefore, 
three rare codons were changed to codons frequently used in E. coli via site-
directed mutagenesis (primer no. 19-22, Table 4, p. 33) to improve the 
expression level. Codons of Arg4 (CGA), Leu10 (CTA), Ile11 (ATA) were 
exchanged by the frequently found E. coli codons CGC (Arg4), CTG (Leu10), 
ATT (Ile11), respectively. 
The complete sequences of all final constructs were afterwards checked by 
MWG Biotech AG, Ebersberg. Subsequently, the conctructs were transformed 
into the following CaCl2-competent expression hosts based on BL21 (DE3) 
and expression levels were checked at 37 °C, 17 °C, and 20 °C, respectively: 
BL21 (DE3) pLysS, RosettaTM 2, CodonPlus®-RIL, GOLD.  
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1) According to diploma theses of Johannes Schulze Wischeler and Christian Hasewinkel [1,2]. 
2) According to Table 4, p. 11. 
3) All expression experiments were performed under the following conditions: 1 mM IPTG, 3 h, 37 °C. Additionally tested conditions are 
annotated explicitly as follows: a) 1 mM IPTG, 6 h, 20 °C; b) 1 mM IPTG, 10 h, 17 °C; c) 1 mM IPTG, 4 h, 30 °C. 
4) In multi cloning site II (MCS II) 
5) Codons of Arg4 (CGA), Leu10 (CTA), Ile11 (ATA) were mutated to the frequently found E. coli codons CGC (Arg4), CTG (Leu10), ATT (Ile11), 
respectively (primer numbers: 19-22). 
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Results of all expression tests are listed in Table 2 (p. 23). In most cases 
successful overexpression could be obtained but frequently, the resulting 
protein was present in form of inclusion bodies. Co-expression of ipaA and 
the sequence encoding the Vinculin head domain failed, while co-expression 
of the chaperone Spa15 had no significant influence on the solubility of 
IpgB2, OspD1, and IpaA. Similarly, deletion of the first 20 N-terminal amino 
acids seems not to take dramatic influence on protein solubilities. GST-
tagging resulted only in case of IpgE in a partially better solubility of the 
overproduced gene product. In most cases, expression in BL21 (DE3) 
CodonPlus®-RIL performed best. This expression host provides additional 
tRNA molecules decoding ‘rare codons’ thus featuring a higher expression 
rate for foreign genes with ‘unusual codons’.  
2.2 Purification of Pathogenicity Factors IpgB2, OspD1 and IpgE 
Purification of proteins from inclusion bodies is usually performed under 
denaturing conditions (6 M guaninidinium chloride/ 8 M urea) yielding 
unfolded protein and therefore requires a subsequent refolding step. Thus, 
in the first attempts only the soluble fractions of expression experiments 
were further examined. Only in case of IpgB2, OspD1 and IpgE at least 
partially soluble overexpression products were detected. Hence, these three 
pathogenicity factors were purified under native conditions. 
2.2.1 IpgB2 
After cell lysis GST-tagged IpgB2 and IpgB2-20 (from production in 
BL21 (DE3) CodonPlus®-RIL containing plasmid no. 7 (pCH4, Table 2, p. 23), 
at 1 mM IPTG, 3 h, 37 °C) were purified from the cell lysate by addition of 
glutathione sepharose, equilibrated in PBS (Phosphate Buffer Saline) and 3 h 
incubation at 20 °C. After several PBS washing steps, PreScissionTM protease 
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(GE Healthcare) were added to release free IpgB2, and IpgB2-20, respectively, 
during over night incubation. However, the small amount of protein gained 
from first expression experiments was not sufficient to successfully observe 
cleaved, GST-free IpgB2(-20). In addition untagged IpgB2(-20) may be less 
soluble, compared to the GST-tagged version, putatively leading to its 
precipitation [2]. 
2.2.2 OspD1 
GST-tagged OspD1 (from production in BL21 (DE3) CodonPlus®-RIL 
containing plasmid no. 11 (527, Table 2, p. 23), at 1 mM IPTG, 3 h, 37 °C) 
was purified via glutathione sepharose, as described for IpgB2. After several 
PBS washing steps, elution of GST-OspD1 was achieved upon addition of 
20 mM glutathione. After a subsequent gelfiltration, the sample was 
concentrated to 6 mg/ml utilising Vivaspin columns (Sartorius), yielding 
0.4 mg protein [2]. 
2.2.3 IpgE 
GST-tagged IpgE (from production in BL21 (DE3) CodonPlus®-RIL containing 
plasmid no. 12 (pCH7, Table 2, p. 23), at 1 mM IPTG, 4 h, 30 °C, 2 L culture 
volume) was purified via glutathione sepharose and PreScissionTM protease 
cleavage of the GST-tag, as described for IpgB2. Size exclusion 
chromatography and concentration of the sample yielded 4.5 mg pure 
protein at a final concentration of 8 mg/ml. The protein was characterised by 
MALDI-TOF mass spectrometry (determined mass: 14,433 Da, Figure 6, 
which is in good agreement with the expected value of 14,455 Da) [2].  
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Figure 6: MALDI-TOF mass spectrum of IpgE [2]. 
 
 
2.3 Crystallisation of Pathogenicity Factors OspD1 and IpgE 
Crystallisation was performed by the vapour diffusion technique at 18 °C. 
Initial high-throughput screens were set up at the 200 nl scale using a 
Cartesian pipetting robot and 96-well Greiner sitting drop plates. The 
following commercial screens were used: Sigma Basic, Sigma Extension, 
Nextal Classic, Wizard I and II, PEG-Ions. 
In case of GST-OspD1, no crystals or crystalline patterns appeared inside the 
droplets over a period of about 2 month. Nevertheless, in about 50 % of the 
droplets protein precipitation was observed. Thus, it can be assumed, that 
the applied protein concentration (6 mg/ml) is basically sufficient for a 
further screening. 
In case of IpgE the conditions listed in Table 3, led to the formation of small 
crystals [2]. One crystal with a diameter of about 20-50 m was mounted on 
a rotating anode X-ray source. Upon radiation, no reflections could be 
detected. Salt crystals of similar size would have shown few but strong 
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reflections. Thus, it is likely that these crystals grown under the identified 
conditions, consist of protein and not salt. However, the crystal size has to 
be optimised. 
Table 3: IpgE crystallisation conditions identified by highthroughput screening [2]. 






4 mg/ml 20 % 1,4-Butandiol 
0.2 M Li2SO4 






6 mg/ml 15 % Jeffamin M-600 
25 mM CsCl 






4 mg/ml 15 % Jeffamin M-600 
25 mM CsCl 





2.4 Homology Modelling of Pathogenicity Factors IpaA and IpgE 
Since no experimental phases have been determined yet for the above 
described pathogenicity factors, prospective de novo structure determination 
via X-ray methods requires either the production of non-native protein 
crystals such as seleno methionine or heavy metal derivatives. On the other 
hand, also a homology model could yield appropriate phases by performing 
molecular replacement. In that case, structure solution could be performed 
without the need of synchrotron radiation at variable wavelength. 
In case of IpaA and IpgE, homologues with already known crystal structures 
could be identified in the NCBI GenBank® sequence database [13] via BLAST 
query. The respective Clustal W 1.83 [14] sequence alignments are shown in 
chapter 5.2.3 (Appendix). Sequence identities of IpaA with a Salmonella 
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typhimurium invasion protein (SipA) fragment, and of IpgE with a TTS 
secretion chaperone of Salmonella enterica (SigE) were scored to 29 % 
(IpaA : SipA), and 24 % (IpgE : SigE). Conserved substitutions were observed 
in 27 % (IpaA : SipA), and 29 % (IpgE : SigE), leading to a homology of 56 % 
(IpaA : SipA), and 53 % (IpgE : SigE). Further 15 % (IpaA : SipA), and 14 % 
(IpgE : SigE) were identified as semi-conserved substitutions, respectively. 
Based on these sequence alignments, and the crystal structures of the SipA 
fragment (amino acids 48 – 264, PDB codes 2fm8 – SipA fragment, 2fm9 – 
SipA fragment in complex with InvB, a TTS chaperone) [15] in case of IpaA, 
and SigE (PDB code 1k3s – SigE dimer) [16], in case of IpgE respectively, 
homology models were generated using the program MODELLER [17,18]. 
The IpaA homology model (fragment of amino acids 48 – 261) shows an 
α−helix bundle, consisting of eight helices arranged in a compact fold (Figure 
7a). The IpgE homology model exhibits the SigE fold with α−β−β−β−α−β−β−α 
topology [16] (Figure 7b). 
Figure 7: homology models of IpaA and IpgE. 
a) IpaA homology model for amino acids 48 – 261 (red) and template structure of 
S. typhimurium SipA, 2fm9, chain A (yellow). b) IpgE homology model (blue) and 
template structure of S. enterica SigE, 1k3s, chain A (dark grey) and B (light grey). 
a) b) 
   
Selected Shigella Pathogenicity Factors 31 
 
2.5 Summary and Outlook 
The pathogenicity factor genes ipaA, ipgB2, ospD1, spa15, and ipgE were 
cloned into several plasmid vectors. In case of OspD1 and IpgE  purification 
protocols could be successfully established. Purified IpgE was identified via 
mass spectrometry and crystallisation conditions were detected. 
Future attempts should include the following suggestions: 
• IpaA, Spa15, Vinculin head domain: Codon optimisation, similar to the 
case of IpgE as reported above and separate protein production should 
be considered. Crystallisation screening should be performed with 
separated samples as well as with mixed samples to possibly gain 
crystals of complexes. 
• IpgB2 and OspD1: Larger expression culture volumes, and purification 
of the GST-tagged variants should be tried. Crystallisation screening 
could be carried out with cleaved (tagless), and as well with 
GST-tagged proteins. GST-tagging obviously does not take sufficient 
influence on IpgB2 or OspD1 solubility. Thus, additionally tagless 
expression and purification of both IpgB2 variants, as well as OspD1 
should be carried out directly by refolding from inclusion bodies. This 
procedure would profit from inclusion body purification, where the 
overproduced protein is available with rather low amounts of cellular 
protein impurities. Subsequently, a refolding protocol would have to be 
established. Several methods such as fast or slow, stepwise or 
continuous dilution, as well as additive screening (e.g. redox reagents 
like GSH/GSSG) should be performed. 
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• IpgE: Larger crystallisation droplet volumes have to be tested, 
hopefully leading to protein crystals large enough and suitable for 
X-ray structure analysis. Micro- and macroseeding techniques should 
be attempted, as well as the screening around the identified conditions 
(e.g. variation of the precipitant’s concentration, or the pH of the 
reservoir solution). If crystals could be gained producing diffraction 
patterns of sufficient quality upon X-ray radiation, molecular 
replacement with the homology model, or a poly-alanine model 
retrieved from the homology model could be carried out. As well, 
seleno methionine or heavy metal derivatives of the IpgE crystals 
should be produced in order to determine experimental phases. 
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2.6 Materials and Methods 
2.6.1 Primers used for PCR amplification of pathogenicity factor 
genes from the virulence plasmid pCP301 
Cloning techniques, expression, protein purification and crystallisation 
protocols are described in the diploma theses [1,2]. 
Table 4: Primers used for amplification of genes via PCR attaching restriction sites to the 
3'- and 5'-ends. 
No. Name Sequence 
1 IpaA forward  5'-CGG CAT ATG CAT AAT GTA AAT AAT ACT CAA GCG CC-3' 
2 IpaA backward  5'-CGG CTC GAG TTA ATC CTT ATT GAT ATT CTT TAA TAC-3' 
3 Iba2-Spa15-
strep-f 
5'-CAT ATG GCT AGC GGC GCC GAG AC-3' 
4 Iba2-Spa15-
strep-b  
5'-GTC TCG GCG CCG CTA GCC ATA TG-3' 
5 Spa15-
DUETforward 




5'-GGC AAG CTT ATA AGA CCC CAT TTA AGA TTT CCA TCC-3' 
7 pPR-Iba2-
IpaA-20-f 




5'-CTA ATT CTG TAA TAA TTG ACA TAC CCG CGG TCT CGG 
CGC C-3' 
9 Vin_head_f 5'-GGC GGC GCG CCA TGC CAG TGT TTC ATA CGC GC-3' 
10 Vin_head_b 5'-GGC GCG GCC GCT TCA AGG TCT GGT GGA GGC G-3' 
11 ipgB2-Nde I-f 5'-CCG CAT ATG ATT ATA ATG CTT GGA ACA TCT TTT AAT AAT 
TTT GGA ATC-3' 








5'-GGC CTC GAG TCA GAA AGG CGA TTC TAA ATT TGT AAT 
ATA GTC-3' 
15 ospD1-Nde I-f 5'-CCG CAT ATG TCA ATA AAT AAC TAT GGA TTA CAT CCA 
GC-3' 
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No. Name Sequence 
16 ospD1-Xho I-b 5'-GGC CTC GAG TTA AAA CAA CTC TTG TAT TTT GTC AGA 
AAT AAT ATT AAA CAT GTC-3' 
17 ipgE-Nde I-f 5’-GGC CAT ATG GAA GAT TTA GCA GAT GTT ATT TGC CG-3’ 
18 ipgE-Xho I-b 5’-GCC GGA TCC TTA ATA CCC CTT CAT TCT TCG CGC-3’ 
19 IpgE-mut10-f 5'-GCA GAT GTT ATT TGC CGC GCC TTG GGT ATC C-3' 
20 IpgE-mut10-b 5'-GGA TAC CCA AGG CGC GGC AAA TAA CAT CTG C-3' 
21 IpgE-mut31-f 5'-GCT TGA TGA TGA TGT GCT GAT TTA TAT TGA AAA AGA 
AGG AGA TTC-3' 
22 IpgE-mut31-b 5'-GAA TCT CCT TCT TTT TCA ATA TAA ATC AGC ACA TCA TCA 
TCA AGC-3' 
2.6.2 Buffers, Enzymes 
PreScissionTM protease 2 u/l, GE Healthcare 
gelfiltration column HiLoadTM 26/60 SuperdexTM 200 
320 mL bed volume 
PBS (Phosphate Buffer Saline): 140 mM NaCl 
10 mM Na2HPO4 
2.8 mM KCl 
1.7 mM KH2PO4 
pH 7.3 
GST cleavage buffer: 50 mM Tris/HCl 
pH 7.0 
150 mM NaCl 
1 mM EDTA 
1 mM DTT 
0.2 % (v/v) Triton X-100 
2.6.3 Cleavage of the GST-tag 
After cell lysis GST-tagged proteins were purified from 40 ml cell lysate by 
addition of 2 ml glutathione sepharose, equilibrated in PBS (Phosphate Buffer 
Saline) and 3 h incubation at 20 °C. After several PBS washing steps, 
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200 units of PreScissionTM protease (GE Healthcare) were added with GST 
cleavage buffer to release free tagless proteins, during over night incubation. 
2.6.4 Homolgy modelling 
Amino acid sequences were extracted from the deposited crystal structures 
with PDB codes: 2fm9 (chain A), 2fm8 (chain C), in case of IpaA homolgy 
modeling, and 1k3s (chains A and B), in case of IpgE homolgy modeling, 
respectively. These sequences were aligned with the S. flexneri IpaA, and 
IpgE sequences (from SWISS-PROT [19]), respectively, utilising Clustal W 
1.83 [14]. The sequences aligned with 29 %, and 24 % identities, respectively. 
Based on the alignment, ten homology models for IpaA and IpgE were 
calculated with MODELLER [18]. The best models were selected by picking the 
model with the lowest value of the MODELLER objective function, which is 
reported in the second line of the model PDB file. 
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3 Glu235 is critical for substrate selectivity in TGT 
Glutamate versus glutamine exchange swaps substrate selectivity 
in tRNA-guanine transglycosylase: Insight into the regulation of 
substrate selectivity by kinetic and crystallographic studies1 
Transfer RNA-guanine transglycosylases (TGT, E.C. 2.4.2.29) constitute a 
family of tRNA-modifying enzymes present in all three domains of life. They 
catalyse the base exchange of specific guanine residues in tRNAs by 
7-substituted-7-deazaguanines in a domain specific manner [2,3]. Archaeal 
TGT inserts preQ0 (for chemical formula see Table 5, p. 40) at position 15 of 
the majority of known archaeal tRNAs where it is further converted to 
archaeosine [4]. Bacterial TGT, in contrast, is involved in a pathway 
introducing the hypermodified base queuine (Q) into the anticodon 
position 34 (the “wobble position”) of just four different tRNAs [5] (Figure 8, 
p. 40). These are specific for His, Tyr, Asp and Asn, respectively, and share a 
U33G34U35 sequence in common [6,7]. The enzyme performs the first tRNA 
dependent step in queuine biosynthesis replacing guanine34 (G34) by 
preQ1 [5] (for chemical formula see Table 5, p. 40). This premodified base is 
produced from GTP [8] by means of the queC, queD, queE and queF gene 
products [9,10]. While the exact functions of QueC, QueD and QueE still have 
to be figured out, QueF has been identified as an NADPH-dependent 
oxidoreductase catalysing the reduction of preQ0 to preQ1 [11]. After 
incorporation into tRNA, preQ1 is converted to the functional Q base in two 
subsequent steps performed by S-adenosylmethionine:tRNA ribosyltrans-
ferase-isomerase (QueA) [12-14] and an unknown coenzyme B12-dependent 
enzyme [15]. 
____________________________________________________________ 
1) This chapter is extracted from: Tidten N, Stengl B, Heine A, Garcia GA, Klebe G, Reuter K. J Mol. Biol. 2007; 374 
(3): 764-76. Mutagenesis was performed by both first authors; enzyme purification, kinetic characterisation and 
determination of crystal structures 2z1v, 2pwv were performed by Bernhard Stengl; assay modification and 
determination of crystal structures 2pwu, 2oko, 2pot, 2z1x, 2z1w were performed by Naomi Tidten. 
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Table 5: Structures of natural substrates of bacterial TGT and the inhibitor 2-butyl-1H-
imidazole-4,5-dicarboxylic acid hydrazide (BIH). 
In the line "conformation" the functional group of the Leu231/Ala232 peptide bond 












   
 preQ1 guanine preQ0 




  BIH  
  Kic: 62 M  
The base exchange catalysed by bacterial TGT follows a ping-pong reaction 
mechanism [16] which is well documented by crystal structure analyses of 
TGT from Zymomonas mobilis [17-19] (Figure 9, p. 41). In a first step, tRNA 
binds to TGT and the glycosidic bond of G34 is cleaved via a nucleophilic 
attack of Asp280 producing a covalent TGT•tRNA complex intermediate. 
Subsequently, preQ1 replaces guanine within the binding pocket and is 
incorporated into tRNA in a reverse reaction step. During the base exchange 
step, replacement of guanine by preQ1 requires an adjustment of the binding 
pocket geometry (Figure 9b, c). Both guanine and preQ1 are recognised by 
functional groups of Asp102, Asp156, Gln203, and Gly230. However, to 
distinguish between the two bases, a peptide bond formed by Leu231 and 
Ala232 has to flip. G34-tRNA binding results in a water mediated contact of the 
G34-N7 to the main chain amide of Ala232. Although the moderate resolution 
of the G34-tRNA bound TGT crystal structure does not allow to 
unambiguously extract this structural detail [18], the structure of TGT bound 
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Figure 8: Queuine modification pathway. 
AdoMet: S-adenosylmethionine; B12: coenzyme B12; oQ: epoxyqueuine. 
 
dicarboxylic acid hydrazide (BIH) (Table 5, p. 40), clearly suggests this 
binding mode [20]. In order to permit efficient preQ1 binding the 
composition of the binding pocket has to be altered. Proper recognition of 
the preQ1 amino methyl group requires the CO acceptor functionality of the 
Leu231/Ala232 peptide bond to be exposed instead of the NH donor (Figure 9c, 
p. 41). Both peptide bond geometries are stabilised from the protein interior 
using the side chain carboxyl of Glu235, a residue strictly conserved in all 
bacterial TGTs. Obviously depending on its protonation state, Glu235 either 
donates an H-bond to the backwards oriented carbonyl oxygen or accepts an 
H-bond from the amide of the flipped peptide bond (Figure 9b, c, p. 41). 
Consistently, the peptide switch is also observed in crystal structures of the 
ligand free enzyme in a pH dependent manner. TGT crystals obtained at 
pH 5.5 show the amide of the Leu231/Ala232 peptide bond exposed to the 
binding pocket [19], while the opposite orientation is observed in crystals 
obtained at pH 8.5 (Figure 10d, p. 44).  
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Figure 9: Base exchange mechanism in bacterial TGT. 
 
In addition to preQ1, bacterial TGT in vitro also accepts the biosynthetic 
precursor of preQ1, namely preQ0, as a substrate [19,21]. This substrate 
promiscuity is a consequence of the above-mentioned peptide switch as 
binding of preQ0 is facilitated by the Leu231/Ala232 peptide bond 
conformation required for the accommodation of guanine. Since in bacterial 
cells both preQ0 and preQ1 are present (even at unknown concentrations), 
bacterial TGT must be able to discriminate between these substrates and 
preferentially incorporate preQ1 into tRNA. For Escherichia coli TGT there 
exists evidence that this is achieved through a lower affinity of the enzyme to 
preQ0, since KM determination revealed a six-fold higher value for preQ0 
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(2.4 M) compared to preQ1 (0.4 M) [21] (for Z.  mobilis TGT no kinetic data 
regarding preQ0 and preQ1 have been reported yet). Although the available 
complex structures of preQ0 and preQ1 bound to Z. mobilis TGT do not 
provide an ostensible explanation for this selectivity, they reveal some 
significant differences between the binding modes of the two substrates [19]. 
In the TGT•preQ1 complex structure the Glu235 carboxyl function is clearly 
present in a deprotonated state, promoting the formation of an H-bond 
(2.8 Å) to the main chain amide of Ala232. This results in the exposure of the 
Leu231 main chain carbonyl into the binding pocket enabling it to interact 
with the presumably protonated and thus positively charged amino methyl 
group of preQ1 (Figure 10b, p. 44). It should be noted that in this scenario 
the charges of the Glu235 carboxylate and the protonated preQ1 amino methyl 
group compensate for each other. 
In the TGT•preQ0 complex the Leu231/Ala232 peptide bond is flipped 
compared to the preQ1 bound situation, i.e. the Ala232 main chain amide is 
facing the binding pocket, where it H-bonds the ligand’s acceptor nitrile 
group. As mentioned above, this conformation of the Leu231/Ala232 peptide 
bond exactly corresponds to the one observed upon binding of the guanine 
analogue inhibitor BIH. However, the way this conformation is stabilised by 
the Glu235 side chain carboxyl, is significantly different. Indeed, the Glu235 
carboxyl function does not H-bond in its protonated state the backwards 
oriented Leu231 carbonyl. It rather stacks with its hydrophobic π face between 
the Leu231/Ala232 peptide bond and the aromatic ring system of the Tyr161 
side chain. This stacking interaction is stabilised by H-bonds formed by the 
Glu235 carboxyl group to the main chain amide of Val233 (3.1 Å) and to the 
carbonyl oxygen of Gly230 (2.8 Å). The latter H-bond clearly indicates that 
also here the Glu235 carboxyl function is present in a protonated state. A shift 
of the Glu235 side chain by ca. 1.5 Å towards the binding pocket is 
prerequisite for the stacking interaction. This shift is rendered possible by a 
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Glu235/Gly236 peptide bond flip which so far had not been observed in any 
other TGT crystal structure [19] (Figure 10c, e, p. 44). 
The present work was aimed to confirm and further analyse the role of Glu235 
in the Leu231/Ala232 peptide switch and in substrate promiscuity of bacterial 
TGT. In order to mimic a permanently protonated state of the Glu235 carboxyl 
function we introduced a conservative Glu235Gln mutation into the Z. mobilis 
TGT enzyme. This mutation was expected to firmly fix the peptide switch in 
its NH exposing form independent of the applied pH or any bound substrate. 
This chapter describes the consequences of this mutation on substrate 
specificity of Z. mobilis TGT as studied by means of enzyme kinetics and 
crystal structure analyses. 
Figure 10: Crystal structures of bacterial and archaeal TGT. 
(a) The superposition of bacterial TGT in complex with the TGT inhibitor BIH (C atoms in 
cyan) and guanine (C atoms in grey) shows in both cases an identical conformation for 
the Leu231/Ala232 peptide bond stabilised by an H-bond of the Leu231 carbonyl to the 
protonated Glu235 side chain carboxyl.  
(b) Bacterial TGT in complex with preQ1. The Leu231/Ala232 peptide bond is switched 
compared to the guanine/BIH bound situation stabilised by an H-bond of the Ala232 
amide to the deprotonated Glu235 carboxyl.  
(c) Bacterial TGT in complex with preQ0. The Leu231/Ala232 peptide bond conformation 
corresponds to that observed for guanine/BIH bound TGT, but stabilisation surprisingly 
occurs through a stacking interaction with the protonated Glu235 carboxyl concomitant 
with a Glu235/Gly236 peptide bond flip.  
(d) Superposition of ligand-free bacterial TGT crystallised at pH 5.5 (C atoms in red) and 
pH 8.5 (C atoms in grey). Protonation of Glu235 at pH 5.5 leads to a binding pocket 
geometry observed upon binding of guanine/BIH. Deprotonation of Glu235 at pH 8.5 
results in a geometry as induced upon preQ1 binding.  
(e) Superposition of bacterial TGT and TGT(Glu235Gln) both in complex with preQ0 
reveals identical binding pocket geometries. The Glu235 side chain is stacking between 
the aromatic ring system of Tyr161 and the Leu231/Ala232 peptide bond (encircled).  
(f) Archaeal TGT with bound preQ0. The amide group of the Val197/Val198 peptide bond 
(corresponding to Leu231/Ala232 in bacterial TGT) is unable to flip. It permanently 
exposes the Val198 NH, since the opposing Val197 CO is involved in an invariant backbone 
H-bond network. 
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3.1 Results 
3.1.1 Crystal structure of wild type Z. mobilis TGT in complex with 
guanine 
The crystal structure of Z. mobilis TGT in complex with the inhibitor 2-butyl-
1H-imidazole-4,5-dicarboxylic acid hydrazide (BIH) had shown, for the first 
time, a conformation of the Leu231/Ala232 peptide bond, in which the main 
chain amide of Ala232 was exposed to the binding pocket [20]. This had been 
in contrast to all other crystal structures of Z. mobilis TGT determined 
previously, where this peptide bond was oriented such that the main chain 
carbonyl of Leu231 was facing the binding pocket. Since guanine just like BIH 
lacks the exocyclic aminomethyl group of preQ1, it had immediately been 
postulated that binding of guanine to TGT resulted in the same conformation 
of the Leu231/Ala232 peptide bond as binding of BIH. Due to the lack of a high 
resolution crystal structure of guanine-bound TGT, this assumption had not 
yet been proven so far. Thus, in order to figure out the exact geometry of the 
TGT binding pocket with guanine bound, we crystallised Z. mobilis TGT in the 
presence of guanine hydrochloride and determined the complex structure at 
a resolution of 1.77 Å (Table 7, p. 62). In the electron density map the bound 
ligand was clearly defined. As observed for the TGT•BIH complex, the 
Leu231/Ala232 peptide bond was present in the NH exposing conformation 
stabilised by a strong H-bond (2.4 Å) which was formed between the 
backwards oriented Leu231 carbonyl oxygen and the protonated carboxyl 
group of Glu235. Also in absolute accordance with the situation in the 
TGT•BIH complex an interstitial water was bound H-bonding both the Ala232 
main chain amide and the guanine N7 (Figure 10a, p. 44). Thus, the 
presented structure confirmed that binding of guanine by TGT leads to the 
same Leu231/Ala232 peptide bond orientation and Glu235 conformation as 
binding of the BIH inhibitor. 
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3.1.2 Enzymatic characterisation of wild type Z. mobilis TGT 
Since no kinetic data were available for the Z. mobilis TGT enzyme regarding 
preQ0 and preQ1 we determined and accordingly redetermined kcat and KM 
concerning guanine, preQ0, preQ1 and tRNA. Redetermination of the 
Michaelis/Menten parameters for guanine and tRNA was done by means of a 
well established assay monitoring the incorporation of radio-labelled 
guanine into tRNA [22]. Since no radio-labelled preQ0 and preQ1 is 
commercially available, we used for these substrates a guanine washout 
assay which in essence was first described by Hoops et al. [21] Here, the 
decrease of radioactivity in tRNA labelled in position 34 with [8-3H]-guanine 
due to the incorporation of the respective substrate is monitored. The kinetic 
parameters for all four substrates are summarised in Table 6 (p. 47). With 
respect to preQ0 and preQ1 the six-fold difference in KM reported for the 
E. coli enzyme was not observed for Z. mobilis TGT. Within the experimental 
errors the KM-values of preQ0 and preQ1 were virtually identical and did not 
differ from that measured for guanine. Instead, the kcat-values of preQ0 and 
preQ1 differed significantly by a factor of almost 10. While, compared to 
guanine, preQ1 was incorporated into tRNA with a higher rate, the 
incorporation rate of preQ0 was substantially lower than that of guanine. 
Obviously, in contrast to E. coli TGT, in Z. mobilis TGT the preferred insertion 
of preQ1 into tRNA is not achieved by a higher affinity of preQ1 to the enzyme 
compared to preQ0, but by a clearly higher turnover number. 
Table 6: Kinetic parameters for wild type TGT and TGT(Glu235Gln). 
wild type Tgt tRNATyr * [3H]-guanine preQ1 preQ0 
KM [M] 0.9 ± 0.2 1.2 ± 0.2 0.7 ± 0.2 0.9 ± 0.2 
kcat [s-1] ** 5.4 ⋅ 10-2 5.6 ⋅ 10-2 10.2 ⋅ 10-2 1.2 ⋅ 10-2 
kcat/KM [M-1s-1] 6.0 ⋅ 10-2 4.6 ⋅ 10-2 14.6 ⋅ 10-2 1.3 ⋅ 10-2 
     
Tgt(Glu235Gln) tRNATyr * [3H]-guanine preQ1 preQ0 
KM [M] 1.0 ± 0.1 3.3 ± 0.3 32 ± 7 < 0.5  
kcat [s-1] ** 7.0 ⋅ 10-2 7.6 ⋅ 10-2 10.0 ⋅ 10-2 0.6 ⋅ 10-2 
kcat/KM [M-1s-1] 7.0 ⋅ 10-2 2.4 ⋅ 10-2 0.3 ⋅ 10-2 > 1.2 ⋅ 10-2 
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3.1.3 Construction and enzymatic characterisation of Z. mobilis 
TGT(Glu235Gln) 
To further investigate the influence of the Glu235 carboxyl on the 
Leu231/Ala232 peptide switch and thus on substrate selectivity we introduced 
a Glu235Gln mutation into Z. mobilis TGT by site directed mutagenesis. The 
carboxamide of the mutated residue was intended to mimic a permanently 
protonated and electrically neutral Glu235 side chain carboxyl. Subsequently, 
we determined Michaelis/Menten parameters for the mutated enzyme 
concerning guanine, preQ0, preQ1 and tRNA. The results are summarised in 
Table 6. As expected, the mutation had no significant influence on the 
affinity of the tRNA substrate reflected by a virtually unchanged KM compared 
to wild type TGT. A slight increase of kcat (7.0 • 10-2 s-1 vs. 5.4 • 10-2 s-1 
measured for the wild type enzyme) using guanine as second substrate was 
not considered significant with respect to the error range of the assay. Alike, 
the Glu235Gln mutation obviously had no influence on the turnover numbers 
for any of the three substrate bases. The kcat values regarding guanine, preQ0 
and preQ1 determined for the mutated enzyme agreed well with those 
determined for the wild type enzyme. In contrast, however, the mutation 
caused a measurable change in KM with respect to the substrate bases. While 
KM(guanine) was only marginally changed, the most drastical impact of the 
mutation was observed for KM(preQ1). Although this base was still accepted 
as a substrate, KM was increased by a factor of almost 50 suggesting a 
noticeable decrease in affinity. Unlike guanine and preQ1, preQ0 seemed to 
bind with an increased affinity to the mutated enzyme as KM for this 
substrate was, compared to wild type TGT, lowered from 0.9 M to less than 
0.5 M. Due to the slow turnover rate achieved by TGT, in particular with 
respect to this substrate, an exact determination of KM was not possible. To 
assure an excess of substrate even at low concentrations the amount of 
enzyme used in the assay would have had to be kept too low to obtain a 
reasonable signal to noise ratio. 
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In summary, while the Glu235Gln mutation had no significant influence on the 
turnover number for any of the three substrate bases, KM was drastically 
increased for preQ1, marginally elevated for guanine and obviously lowered 
(even though to an unknown extent) for preQ0. Thus, regarding kcat/KM as a 
measure of catalytic efficiency, the Glu235Gln mutation resulted in a clearing 
or even inversion of substrate preference from preQ1 to preQ0 (see Table 6, 
p. 47). This agrees well with the hypothesis, that the Leu231/Ala232 peptide 
conformation necessary for guanine and preQ0 accommodation is in wild 
type TGT stabilised by the protonated state of Glu235, which was mimicked by 
the Glu235Gln mutation. 
3.1.4 Crystal structure analyses of TGT(Glu235Gln) 
To allow the interpretation of the measured enzyme kinetic data at a 
structural level, we crystallised the mutated enzyme in its apo form as well as 
in complex with its substrates and the guanine analogous inhibitor BIH (Table 
7, p. 62). 
Two structures of ligand-free TGT(Glu235Gln) derived from crystals grown at 
pH 5.5 and pH 8.5, respectively, were determined at nominal resolutions of 
better than 1.6 Å. In the electron densities of both structures the residues of 
and near the active site were excellently defined. As expected, in contrast to 
wild type TGT no pH-dependent conformational change was observed for the 
Leu231/Ala232 peptide bond. Independently whether crystallisation had been 
performed at pH 5.5 or 8.5, the carbonyl of this peptide bond was oriented 
backwards while the amide was exposed into the binding pocket. 
Surprisingly, however, the way this conformation was stabilised by the Gln235 
carboxamide did not correspond to the way it is stabilised by the protonated 
Glu235 carboxyl in wild type apo TGT crystallised at pH 5.5. Rather, the 
geometry of the binding pocket was virtually identical to the one observed in 
the structure of wild type TGT with preQ0 bound. No H-bond was formed     
. 
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Figure 11: Crystal structures of 
TGT(Glu235Gln). 
(a) Superposition of TGT(Glu235Gln) in its 
apo form (crystallised at pH 5.5; the 
structure obtained at pH 8.5 looks 
identical) and in complex with preQ0 
reveals equal binding pocket geometries. 
(b) 2|Fo| - |Fc| electron density map of 
TGT(Glu235Gln) in complex with guanine 
contoured at 1.5 σ (blue). The green 
density represents an |Fo| - |Fc| map with 
the ligand omitted from the calculation 
contoured at 3.0 σ. 
(c) 2|Fo| - |Fc| electron density map of 
TGT(Glu235Gln) in complex with preQ1 
contoured at 1.5 σ (blue). The green 
density represents an |Fo| - |Fc| map with 
the ligand omitted from the calculation 
contoured at 3.0 σ. The electron density 
reveals a split conformation for the 
Asp102 side chain indicating an 
uncomplete occupancy of the binding 
pocket with the substrate base. The 
Leu231/Ala232 peptide bond is present in 
two different conformations. The 
occupancy of the ligand and of the 
predominant Leu231/ Ala232 and Asp102 
conformers refine to 0.7. 
between the Gln235 carboxamide 
and the Leu231 carbonyl oxygen. 
Instead, the carboxamide stacked 
between the Leu231/Ala232 peptide 
bond and the side chain aromatic 
ring system of Tyr161. As a 
consequence, the Gln235 side chain 
was shifted towards the binding 
pocket concomitant with a 
Gln235/Gly236 peptide flip so far only 
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observed in preQ0 bound wild type TGT (with Gln235 being replaced by 
Glu235). To investigate the influence of a bound substrate on the active-site 
geometry of TGT(Glu235Gln), we determined the crystal structures of the 
mutated enzyme in complex with preQ0, guanine, the BIH inhibitor, and 
preQ1, respectively. 
The TGT(Glu235Gln)•preQ0 complex structure was determined at a resolution 
of 1.70 Å. The electron density for the preQ0 ligand was clearly defined. 
Superposition of the TGT(Glu235Gln)•preQ0 complex structure and the 
structures of the ligand-free mutated enzyme revealed that the binding 
pocket geometry was virtually identical in all three structures (Figure 11a, 
p. 50) and exactly corresponded to the one observed in preQ0 bound wild 
type TGT (Figure 10e, p. 44). The nitrile nitrogen of preQ0 was present at a 
position occupied by a glycerol oxygen picked up from the cryo buffer in the 
structures of uncomplexed mutated TGT (Figure 11a, p. 50). 
The crystal structures of TGT(Glu235Gln) in complex with guanine and with 
the guanine analogous inhibitor BIH were determined at a resolution of 
1.80 Å and 1.63 Å, respectively. In both structures the electron densities for 
the ligands as well as for the residues constituting the binding pockets were 
excellently defined (for the guanine complex see Figure 11b (p. 50). It was 
clearly visible that also binding of guanine or BIH did, compared to the apo-
form, not result in any conformational change of the Leu231/Ala232 peptide 
bond or of Gln235. As in guanine or BIH-bound wild type TGT, the exposed 
Ala232 main chain amide formed an H-bond to an interstitial water molecule, 
which was further H-bonded to N 7 of guanine or the corresponding nitrogen 
of BIH, respectively. In contrast to wild type TGT, however, this conformation 
was not stabilised by an H-bond formed between the Leu231 carbonyl and the 
carboxamide of Gln235 but by a stacking interaction between the 
Leu231/Ala232 peptide bond and the Gln235 side chain. 
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In order to understand the way preQ1 was bound by the mutated TGT we 
determined the crystal structure of the TGT(Glu235Gln)•preQ1 complex at a 
resolution of 1.63 Å. Also in this structure the electron density attributable to 
the ligand was very well defined. A split conformation of the Asp102 side 
chain, however, indicated an incomplete occupancy of the binding pocket 
with preQ1 (Figure 11c, p. 50). In apo structures of TGT the Asp102 side chain 
carboxylate is oriented towards the outside of the binding pocket H-bonding 
the side chain amide of Asn70 as well as the main chain amide of Thr71. Once 
a substrate base has bound, the Asp102 side chain rotates into the binding 
pocket towards the ligand in order to H-bond its exocyclic amine at 
position 3 [23]. In the TGT(Glu235Gln)•preQ1 complex structure ca. 30 % of 
Asp102 exhibited a side chain conformation pointing towards the outside of 
the binding pocket suggesting a portion of the binding pocket being 
unoccupied by the ligand. This was in line with the fact that KM(preQ1) was 
drastically increased for TGT(Glu235Gln). As in all other structures of 
TGT(Glu235Gln) the Gln235 side chain stacked on top of the Leu231/Ala232 
peptide bond. Accordingly, the conformation of the Gln235/Gly236 peptide 
bond remained also here unchanged compared to all other TGT(Glu235Gln) 
structures as well. Interestingly, however, the electron density attributable to 
the Leu231/Ala232 peptide bond could only been interpreted such that it was 
present in two different conformations. One conformer corresponded exactly 
to the one observed in the remaining TGT(Glu235Gln) structures with the main 
chain amide of Ala232 being exposed to the binding pocket. Indeed, this 
conformation was hardly compatible with a bound preQ1 molecule due to 
unfavourable interactions between the Ala232 main chain amide and the 
amino methyl group of preQ1. The fact that this conformation could be 
refined to an occupancy of ca. 30 % agreed well with the assumption that a 
portion of the binding pocket was devoid of ligand. In the second conformer 
the Leu231/Ala232 peptide bond was flipped enabling the exposed Leu231 
carbonyl oxygen to H-bond the amino methyl group of preQ1. This geometry 
combining the exposed Leu231 carbonyl with the stacking conformation of 
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Gln235 (or Glu235) had never been observed in any TGT crystal structure 
before. As a consequence, exposure of the Leu231 carbonyl into the binding 
pocket does not necessarily require the deprotonated carboxyl of Glu235 
H-bonding the backwards oriented Ala232 main chain amide. It is also 
compatible with a stacking interaction of the Gln235 side chain, although this 
mode of stabilisation is obviously energetically less favourable as reflected by 
the drastically increased KM(preQ1) measured for TGT(Glu235Gln). 
3.2 Discussion 
In this study we have confirmed and further analysed the role of Glu235 as a 
general acid/base not directly involved in catalysis but facilitating the binding 
of various substrates with different H-donor and -acceptor properties. The 
high resolution crystal structure of Z. mobilis TGT in complex with guanine 
presented in this work gives the final proof that binding of each of the three 
substrate bases (guanine, preQ0 and preQ1) triggers a different geometry of 
the TGT binding pocket. Prerequisite of the substrate promiscuity observed 
in TGT is the ability of the Leu231/Ala232 peptide bond to flip and thus to 
change its orientation depending on the bound substrate. Remarkably, the 
bound substrate not only influences the orientation of this peptide bond but, 
moreover, the way it is stabilised by the strictly conserved Glu235. Obviously, 
the highly flexible interplay of the Leu231/Ala232 peptide bond and the general 
acid/base Glu235 facilitates an optimal adaptation of the TGT binding pocket 
to each of its substrate bases. This is reflected by the virtually identical KM 
values of Z. mobilis TGT for guanine, preQ0 and preQ1 as determined in this 
study. Moreover, our results show that the preferred incorporation of the 
"correct" substrate preQ1 into tRNA over its biosynthetic precursor preQ0 is 
achieved by a ca. 10 fold faster turnover rate. It should be noted, however, 
that to the best of our knowledge it has not been investigated so far, if QueF, 
the nitrile reductase reducing preQ0 to preQ1, is also acting on preQ0 
incorporated into tRNA. In this case preQ0 could represent an in vivo 
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substrate of TGT as well. The observed differences in kcat for the three 
substrate bases may hardly be explained by their binding modes observed in 
the corresponding crystal structures, but possibly may be deduced from their 
chemical properties. In each case nitrogen N9 of the respective base 
nucleophilically attacks C1 of the covalently bound tRNA ribose34 during 
catalysis (Figure 9c, p. 41 and Table 5, p. 40). In preQ1 this nitrogen is the 
most potent nucleophile, as it is in no electronic conjugation with the 
exocylic amino methyl group. In guanine, N9 is less nucleophilic due to an 
electron withdrawing effect of N7 being in conjugation with N9. The preQ0 
substrate is the least reactive base in this series. Here, the exocyclic nitrile 
function is conjugated to the endocyclic nitrogen, resulting in an even more 
pronounced electron withdrawing effect. This is fully consistent with the 
observed decrease in turnover in the order preQ1 > guanine > preQ0. The 
virtually identical KM-values for the three substrate bases indicate that the 
conformation of the Leu231/Ala232 peptide bond as well as the way it is 
stabilised by the Glu235 side chain carboxyl may have little influence on the 
energetic state of the substrate binding pocket. 
With intent to create a bacterial TGT with altered substrate specificity Glu235 
was mutated to Gln in an attempt to mimic a permanently protonated Glu235 
side chain carboxyl. Since the Leu231/Ala232 peptide bond conformation 
required for the accommodation of preQ1 involves stabilisation by a 
deprotonated Glu235 the mutation was expected to strongly disfavour or even 
disable preQ1 binding while leaving unaffected or even improving the binding 
of guanine and preQ0. Kinetic characterisation of TGT(Glu235Gln) showed that 
the change of KM(guanine) caused by the mutation was at the border of 
significance, while KM(preQ0) was (to an unknown extent) decreased 
compared to wild type TGT. Although KM(preQ1) of the mutated enzyme was 
increased by a factor of almost 50, the remaining affinity to this substrate 
was still unexpectedly high. The crystal structures of TGT(Glu235Gln) in its 
apo-form as well as in complex with various ligands provided an explanation 
to the observed kinetic data. The same geometry of the binding pocket was 
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observed, no matter if the mutated enzyme was crystallised in its apo-form 
(independent of the applied pH) or in complex with guanine, BIH, or preQ0. In 
each case, the Ala232 main chain amide was exposed to the binding pocket, 
stabilised by a stacking interaction with the Gln235 side chain carboxamide. 
This conformation was analogous to that observed in wild type TGT bound to 
preQ0. Seemingly, a surprisingly strong H-bond formed between the Leu231 
carbonyl and the protonated Glu235 side chain carboxyl (2.4 Å) plays an 
important role in stabilising the binding pocket geometry observed in wild 
type TGT crystallised at pH 5.5 or in complex with guanine/BIH. Due to its 
less electronegative nitrogen and the presence of two hydrogens over which 
the positive partial charge is distributed the carboxamide of Gln235 is 
obviously not able to form as strong an H-bond to the Leu231 carbonyl 
rendering the stacking interaction energetically more favourable. Hence, the 
binding pocket of TGT(Glu235Gln) seems predestined for the accommodation 
of preQ0, since independent of any pH no structural rearrangement is 
required for its binding. A priori the binding pocket is present in a geometry 
identical to the one induced upon preQ0 binding in wild-type TGT. This 
finding is supported by the (even though to an unknown extent) reduced 
KM(preQ0) determined for TGT(Glu235Gln). As a surprise, the crystal structure 
of TGT(Glu235Gln) in complex with preQ1 revealed a binding pocket geometry 
featuring an exposed Leu231 carbonyl stabilised by a Gln235 stacking 
interaction. This unexpected geometry showed that the stacking interaction 
still allows the Leu231/Ala232 peptide flip. As a result, the substrate specificity 
achieved by the Glu235Gln mutation was not as strict as that observed for 
archaeal TGT which is absolutely unable to bind preQ1. It permanently 
exposes the amide group of the Val197/Val198 peptide bond (corresponding to 
Leu231/Ala232 in bacterial TGT) allowing both the binding of guanine and of 
preQ0 but not of preQ1. The peptide flip necessary to accommodate this base 
is rendered impossible, since the opposing carbonyl of this peptide bond is 
involved in an invariant backbone H-bond network which does not imply the 
carboxyl group of an acidic amino acid [2,24] (Figure 10f, p. 44). 
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In summary, the mutated TGT(Glu235Gln) investigated in this study behaved 
in several details different from what was expected, although a more 
conservative exchange than glutamic acid / glutamine can hardly be 
performed. The present work clearly shows the indispensability of crystal 
structure analyses for the correct interpretation of kinetic data obtained from 
mutated proteins. 
Furthermore, this study provides an example that mutation of a residue 
which does not even directly interact with any ligand enables the inversion of 
substrate selectivity of an enzyme. This may generally underline the 
importance to consider residues in the "second sphere" of binding pockets 
during attempts of creating enzymes with new binding properties.  
The successful modulation of selectivity is an important step towards the 
understanding of selectivity and specificity determining features in TGTs. In 
E. coli TGT replacement of Asp156 (Z. mobilis numbering) by Asn altered the 
specificity towards xanthine even though at the expense of a reduced 
catalytic activity [25]. In this context it might be interesting to study 
mutational exchanges in the close neighbourhood of the attacking 
nucleophile Asp280. In bacterial TGT this residue is tightly kept in position by 
H-bonds formed with Gly261 and Tyr258 [18]. In archaeal TGT the tyrosine is 
replaced by a strictly conserved histidine [2]. Likely, this exchange will have 
pronounced influence on the catalytic properties. 
These considerations provide a perspective towards an ambitious goal: the 
modification of substrate specificity towards bases other than preQ0 or preQ1 
and their efficient incorporation into the wobble position of tRNAs. This 
would allow to study the translational process in more detail via well 
designed modulation of the accuracy of the wobble base pairing. 
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3.3 Summary 
Bacterial tRNA-guanine transglycosylase (TGT) catalyses the exchange of 
guanine in the wobble position of particular tRNAs by the modified base 
preQ1. In vitro, however, the enzyme is also able to insert the immediate 
biosynthetic precursor, preQ0, into those tRNAs. This substrate promiscuity is 
based on a peptide switch in the active site, gated by the general acid/base 
Glu235. The switch alters the properties of the binding pocket to allow either 
the accommodation of guanine or preQ1. The peptide conformer recognising 
guanine, however, is also able to bind preQ0. To investigate selectivity 
regulation, kinetic data for Z. mobilis TGT were recorded. They show that 
selectivity in favour of the actual substrate preQ1 over preQ0 is not achieved 
by a difference in affinity but via a higher turn-over rate. Moreover, a 
TGT(Glu235Gln) variant was constructed. The mutation was intended to 
stabilise the peptide switch in the conformation favouring guanine and preQ0 
binding. Kinetic characterisation of the mutated enzyme revealed that the 
Glu235Gln exchange has, with respect to all substrate bases, no influence on 
kcat. In contrast, KM(preQ1) is drastically increased while KM(preQ0) seemes to 
be decreased. Hence, regarding kcat/KM as an indicator for catalytic efficiency, 
selectivity of TGT in favour of preQ1 is abolished or even inverted in favour of 
preQ0 for TGT(Glu235Gln). Crystal structures of the mutated enzyme confirm 
that the mutation strongly favours the binding pocket conformation required 
for the accommodation of guanine and preQ0. The way this is achieved, 
however, significantly differs from what was predicted based on crystal 
structures of wild type TGT. 
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3.4 Materials and Methods 
3.4.1 Cloning and TGT preparation 
The QuikChangeTM site-directed mutagenesis kit (Stratagene) was used to 
introduce a Glu235Gln mutation into the wild type tgt expression plasmid 
pET9d-ZM4 [26] following the vendor’s protocol. The primers used for 
mutagenesis were E235Q-s (5’-GGG GGA TTG GCT GTG GGT CAA GGA CAG 
GAT GAA ATG-3’) and E235Q-a (5’-CAT TTC ATC CTG TCC TTG ACC CAC 
AGC CAA TCC CCC-3’) (mutation underlined). Sequencing of the entire tgt 
gene (MWG Biotech, Ebersberg) confirmed the presence of the desired 
mutation as well as the absence of any further unwanted mutation. 
Subsequently, the mutated plasmid pET9d-ZM4-E235Q was transformed into 
E. coli BL21 (DE3) pLysS cells. These cells were used for the preparation of 
the TGT enzyme following the method described by Romier et al. [27]. 
3.4.2 Preparation of tRNATyr 
Preparation of E. coli tRNATyr (ECY2) via in vitro transcription was done 
following the method described by Curnow et al. [28]. 
3.4.3 Kinetic parameters 
Kinetic parameters for TGT and TGT(Glu235Gln) have been determined for the 
different substrates essentially as described in Meyer et al. [22]. 
Michaelis-Menten parameters for tRNA and guanine were determined 
monitoring incorporation of radioactively labelled guanine into tRNATyr in 
position 34. Kinetic data for both substrates were determined separately in 
triplicate and average values were calculated. Kinetic parameters for guanine 
were measured using 150 nM TGT, 15 M unlabelled tRNATyr, and variable 
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concentrations of [8-3H]-guanine (0.9 Ci/mmol,; Hartmann Analytic) in the 
range of 0.5 – 20 M in buffer solution (200 mM HEPES pH 7.3, 20 mM 
MgCl2) and 2.95 M (≡ 5 % of critical micellar concentration) Tween 20 
(Roth). Kinetic parameters for tRNA were measured using 150 nM TGT, 20 M 
[8-3H]-guanine, and variable concentrations of tRNATyr (0.25 – 15 M). Initial 
velocities of the base exchange reaction in counts per minute were converted 
to [M/min] using a calibration constant derived from liquid scintillation 
counting of [8-3H]-guanine solutions with variable concentrations. Kinetic 
parameters were determined via double-reciprocal linearisation using the 
method of Eadie-Hofstee and linear regression using GraFit [29]. 
Michaelis-Menten parameters for preQ0 and preQ1 were calculated via 
monitoring the loss of [8-3H]-guanine from tRNATyr radio-labelled in 
position 34. To produce radioactively labelled tRNA 50 M unmodified 
tRNATyr was incubated with 0.5 M TGT and 10 M [8-3H]-guanine 
(11.8 Ci/mmol, Hartmann Analytic) in TGT assay buffer for 2 h. TGT and free 
guanine/ [8-3H]-guanine were extracted from the reaction mixture by the 
addition of equal volumes of Roti-Phenol (Roth) and chloroform : 
isoamylalcohol (24:1). The aqueous supernatant was once more treated with 
an equal volume of chloroform : isoamylalcohol (24:1). From the aqueous 
supernatant containing the radioactively labelled tRNA samples were retained 
to determine the specific activity of the radio-labelled tRNA. An additional 
purification step was performed via gel filtration using NAP-columns (GE 
Healthcare, Life Science) and TGT assay buffer. From the eluted solution 
again samples were retained to derive the final concentration of the radio-
labelled tRNA from its specific activity. For each preparation it amounted to 
ca. 20 M. Kinetic parameters for preQ0 and preQ1 were measured using 
150 nM wild type TGT or TGT(Glu235Gln) and 8 M radio-labelled tRNATyr. 
The concentration of preQ0 was varied in a range of 0.5 – 15 M. For preQ1 
variable concentrations in a range of 0.5 - 15 M for wild type TGT and 2 – 
80 M for TGT(Glu235Gln) were applied. Initial velocities in counts per minute 
were calculated from the decreasing tritium labelling level of tRNA due to the 
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incorporation of the respective substrate bases. Initial velocities in counts per 
minute were converted to [M/min] using a calibration constant derived from 
liquid scintillation counting of guanine/ [8-3H]-guanine solutions with 
variable concentrations. Kinetic parameters were determined via double-
reciprocal linearisation using the method of Eadie-Hofstee and linear 
regression using GraFit [29]. 
3.4.4 Crystal structure analyses 
TGT(Glu235Gln) crystals suitable for ligand soaking were produced in a two 
step procedure. Droplets were prepared by mixing 2 L of concentrated 
protein solution (14 mg/mL) with 2 L reservoir solution [100 mM MES, 
pH 5.5, 1 mM DTT, 13 % (w/v) PEG 8,000, 10 % (v/v) DMSO]. Micro-crystals 
were grown at 291 K using the hanging-drop vapour diffusion method in the 
presence of 1.0 mL of reservoir solution of the respective seeding buffer. 
Micro crystals grew within two weeks. 
Subsequently, macro-seeding was performed under similar conditions to 
obtain crystals of the uncomplexed protein. Again droplets were prepared by 
mixing 2 L of concentrated protein solution with 2 L macro-seeding 
reservoir solution [100 mM MES, pH 5.5, 1 mM DTT, 8 % (w/v) PEG 8,000, 
10 % (v/v) DMSO]. One micro-crystal was transferred into this solution. Single 
crystals with a size of approximately 0.7 x 0.7 x 0.2 mm3 grew within two to 
four weeks. 
To obtain crystals of apo-TGT(Glu235Gln) at pH 8.5, buffers were used 
identical to those described above but with 100 mM Tris/HCl pH 8.5 instead 
of 100 mM MES pH 5.5 as buffer system. 
To allow co-crystallisation of the mutated TGT in complex with preQ0 the 
compound was dissolved in DMSO and added to the macro-seeding droplet 
to a final concentration of 20 mM. Crystals of mutated TGT complexed to 
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preQ1, BIH and guanine as well as crystals of wild type TGT bound to guanine 
were produced by a soaking procedure. The compounds were dissolved in 
DMSO and added to 2 L of a crystallisation droplet to a final concentration 
of 10 to 20 mM. Finally, a single TGT crystal was transferred into the droplet 
and soaked for 30 min. 
For data collection, crystals were cryoprotected using glycerol. The glycerol 
and PEG 8,000 concentrations of the macro-seeding buffers were increased 
stepwise by transferring the crystals to six different 2 L cryo-droplets each 
with 5 to 30 min incubation times [glycerol concentrations (v/v): 5 % → 10 % 
→ 15 % → 20 % → 25 % → 30 %; and PEG 8,000 concentrations (w/v): 5.0 % → 
6.3 % → 7.5 % → 8.0 % → 8.8 % → 9.8 %, respectively]. These droplets also 
contained the ligands at equivalent concentrations compared to soaking and 
co-crystallisation conditions. The cryo-soaked crystals were flash-frozen in 
liquid N2. Data sets were collected at cryo conditions (100 K) with CuKα 
radiation (λ = 1.5418 Å) using a Rigaku RU-300 rotating-anode generator at 
50 kV and 90 mA equipped with Xenocs focussing optics and an R-AXIS IV 
detector. All crystals tested exhibited monoclinic symmetry in space group 
C2 containing one monomer per asymmetric unit with Matthews coefficients 
of 2.3 - 2.4. Data processing and scaling was performed using the HKL2000 
package [30]. For all refined structures unit cell dimensions for the crystals, 
data collection and processing statistics are given in Table 7. 
For crystals grown at pH 5.5 coordinates of the apo TGTt crystal structure 
grown at pH 5.5 (PDB-code: 1P0D) were directly applied for initial rigid-body 
refinement of the protein molecule followed by repeated cycles of conjugate 
gradient energy minimisation, simulated annealing and B-factor refinement 
using the CNS program package [31]. For the crystal grown at pH 8.5 the 
coordinates of the apo TGT crystal structure grown at pH 8.5 (PDB-code: 
1PUD) were applied. Refinement at the later stages for all other structures 
was performed with SHELXL [32]. Here, up to 50 cycles of conjugate gradient 
minimisation were performed with default restraints on bonding geometry 
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and B-values: 5 % of all data were used for Rfree calculation. Amino acid side 
chains were fit to σA-weighted 2 |Fo| - |Fc| and |Fo| - |Fc| electron density 
maps using Coot [33]. Water, glycerol molecules, and ligands were located in 
the difference electron density and added to the model for further refinement 
cycles. Anisotropic conjugate gradient refinement resulted in a significant 
improvement of the models built for apo TGT(Glu235Gln) (pH 5.5 and 8.5), 
TGT(Glu235Gln)•BIH, and TGT(Glu235Gln)•preQ1. During the last refinement 
cycles, riding H-atoms were introduced for the protein residues (not for the 
ligand) without using additional parameters. All final models were validated 
using PROCHECK [34]. Data refinement statistics are given in Table 7. 
3.4.5 Protein Data Bank Accession Codes 
The following Protein Data Bank (PDB) accession codes were allocated to the 
crystal structures determined during this work (also given in Table 7): 
TGT•preQ0: 2QII TGT(Glu235Gln)•guanine 2POT 
TGT•guanine: 2PWU TGT(Glu235Gln)•BIH 2Z1W 
TGT(Glu235Gln) pH 5.5: 2OKO TGT(Glu235Gln)•preQ0 2PWV 
TGT(Glu235Gln) pH 8.5: 2Z1V TGT(Glu235Gln)•preQ1: 2Z1X 
3.4.6 Crystallographic Tables 
Table 7: Crystallographic data collection and refinement statistics. 
a) number in parentheses is for highest resolution shell 
b) R(I)sym = Σ |I - 〈I〉| / ΣI with I representing the observed intensities and 〈I〉 representing 
the mean observed intensity 
c) Rwork = Σhkl |Fo - Fc| / Σhkl |Fo|. 
d) Rfree was calculated as for Rwork but on 5 % of the data excluded from the refinement. 
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4 Characterisation of a model system for the human TGT binding 
pocket 
4.1 Introduction 
Transfer RNA–guanine transglycosylases (TGTs, EC 2.4.2.29), evolutionary 
ancient enzymes, are involved in the hypermodification of tRNAs [1]. TGTs 
catalyse a base exchange reaction, excorporating a certain guanine base 
within specific tRNAs and introducing 7-substituted-7-deazaguanines [1,2]. 
The enzymes are found in all three domains of life. Although distinct bases 
are incorporated into tRNA in a domain-specific manner, the catalytic 
subunits of TGTs are structurally well conserved [2].  
The molecular differences of archaeal and bacterial TGTs have been 
discussed in chapter 3. As described, archaeal TGTs exchange a guanine 
base at position 15 within the D-arm of tRNAs and are involved in a 
hypermodification pathway, finally leading to archaeosine-tRNAs [3] (Table 
8). In contrast, in bacteria and eukaryotes, guanine34 of the tRNA anticodon 
loop is exchanged and the final hypermodification product within the tRNAs 
is the base queuine (Table 8). Nevertheless, bacterial and eukaryotic TGTs 
still differ in their in vivo substrate bases (Table 8). Bacterial TGTs 
incorporate a relatively small modified base, namely preQ1, which is 
afterwards further modified to the functional queuine within the tRNA by 
S-adenosylmethionine:tRNA ribosyltransferase-isomerase (QueA) [4-6] and 
an unknown coenzyme B12-dependent enzyme [7]. In contrast, eukaryotic 
TGTs directly incorporate queuine into their tRNA substrates [8]. In bacteria 
and eukaryotes, most likely, the translational properties of the tRNA 
substrates are influenced by these modifications [9,10]. 
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Table 8: Three domains of life: Final tRNA modifications and substrate bases of TGTs.  
TGT Archaeal Bacterial Eukaryotic 
Exchanged 
base 
G15 G34 G34 
   
Substrate 
base 
preQ0 preQ1 queuine 
   
Final tRNA 
modification 
archaeosine queuine queuine 
An evolutionary highly conserved mechanism is assumed to originate from 
an ancient ancestor that existed even before the separation of the three 
domains [2]. Bacterial TGTs have been well characterised by extensive kinetic 
studies and crystal structure analyses of Zymomonas mobilis TGT [11-16]. 
Four specific tRNA substrates are known: tRNATyr, Asp, Asn, His, sharing a 
common U33G34U35 sequence [17,18]. The TGT catalysed reaction follows a 
ping-pong mechanism [19]. First, the tRNA substrate binds to the enzyme 
and Asp280 (Z. mobilis numbering) performs a nucleophilic attack, cleaving 
the N-glycosidic bond of guanine34 at the wobble position of the anticodon 
loop and producing a covalent TGT ⋅ tRNA intermediate complex [20]. 
Subsequently, the modified base preQ1 [21] (Table 8) replaces guanine within 
the binding pocket. In a reverse reaction step, it is incorporated into 
tRNA (Figure 9, chapter 3). 
Bacterial TGTs are homodimers of approximately 43 kDa per monomer [22]. 
In contrast, mammalian TGTs appear to be composed of a heterodimer [23] 
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consisting of one approximately 60 kDa subunit, and one smaller, 
presumably the catalytic subunit. In Homo sapiens, this 44 kDa subunit 
shows high homology to bacterial TGTs (43 % sequence identity between 
H. sapiens and Z. mobilis [24]). In addition, a homology model based on 
Z. mobilis  TGT and the Caenorhabditis elegans sequence (38.4 % sequence 
identity) indicate a very high structural similarity of the active sites of 
bacterial and eukaryotic TGTs (five of seven active site residues are strictly 
conserved) [25]. 
Mutation of the tgt  gene in Shigella flexneri results in a significant loss of 
pathogenicity of the bacterium [26]. Shigellae are the causative agents of 
bacterial dysentery and effect some 600,000 infant deaths per year, mainly in 
developing countries with sub-standard hygiene and water supplies. 
Extensive studies of S. flexneri  have resulted in a detailed understanding of 
the pathogenesis, involving bacterial invasion into colonic epithelial cells 
followed by intracellular multiplication and spreading into adjacent cells [27]. 
The virulence was shown to be multifactorial and is under control of various 
genes encoded by the chromosome and the large virulence plasmid [28]. 
Mutation of the tgt  gene causes a reduced synthesis of the VirF protein, a 
key regulatory protein for the full expression of virulence. This effect is a 
consequence of the less efficient translation of the virF mRNA, presumably 
due to the absence of modified tRNA molecules [26] or a putative riboswitch-
like function of the virF mRNA itself [29]. TGT has been suggested to be able 
to modify the virF mRNA as well, thereby influencing its translation 
competent conformation [29]. In any case, TGT is essentially required by the 
bacterium to produce the virulence factor VirF and its pathogenic phenotype. 
Therefore, TGT has been established as a target for structure-based drug 
design [30]. 
Queuine modification is thought to affect the speed and accuracy of the 
translational process and was reported to exhibit pleiotropic effects on 
cellular metabolism [1]. Hence, to be able to specifically inhibit the bacterial 
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target while having unaffected the human counterpart, it is of utmost 
importance to study selectivity-determining features.  
To date, no crystal structure of an eukaryotic, in particular of human TGT 
(hTGT) is yet available, although multiple sequences of eukaryotic TGTs 
resulting from several genome projects [24,31,32] have been deposited 
during the last years. So far, not even the heterologous production of an 
active eukaryotic TGT could be achieved. Rather, the human TGT catalytic 
subunit was reported to be toxic to E. coli  rendering the isolation of an 
active catalytic subunit of mammalian TGT impossible [24].  
Hitherto, the C. elegans TGT homology model is the only source for a 
comparison of eukaryotic and bacterial TGT active sites in structural 
terms [25]. Romier et al. discussed that most presumably a spatial expansion 
of the binding pocket in eukaryotic TGTs enables the binding of extended 
preQ1-like substrates such as queuine. This enlargement of the binding 
pocket was discussed to be due to an eukaryote-specific Val233Gly (Z. mobilis 
numbering) replacement. A further Cys158Val replacement was suggested to 
facilitate additional van der Waals contacts to the cyclopentenyl moiety of 
queuine [25]. 
The aim of this project is to study the differences between bacterial TGT as a 
drug design target and human TGT as the host’s counterpart. In this study, 
based on Z. mobilis TGT a genetically engineered model system for human 
TGT was designed, to probe the properties of such an extended binding 
pocket. 
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4.2 Results 
4.2.1 Sequence comparisons and homology modelling 
Until now, structural information of eukaryotic TGTs was only gained from a 
homology model of the C. elegans  enzyme [25]. However, in recent years, a 
large number of eukaryotic TGT sequences have been deposited [24,31,32]. 
Since the human TGT sequence is now available [24], a homology model was 
constructed for human TGT based on Z. mobilis TGT crystal structures. The 
sequences were aligned utilising Clustal W 1.83 [33] (chapter 5.2.1, 
Appendix). Based on this alignment, ten homology models for human TGT 
were generated with MODELLER 6a [34,35]. The best scored model is shown 
in Figure 12b. It can be clearly seen that the residues inside the binding 
pocket are in general highly conserved among bacterial and eukaryotic TGTs 
(Figure 12a). As in the C. elegans  TGT homology model [25], also in the 
human TGT model, a Val233 (Z. mobilis numbering)/ Gly216 (human TGT 
numbering) exchange can be identified as the crucial difference between the 
human and bacterial TGT binding pockets. This leads to an enlarged binding 
pocket which is required for queuine binding. The replacement of 
Cys158/Val145 is observed as well (Figure 12a, b). Thus, as expected, 
considerations of Romier et al. [25] for the C. elegans model are also found 
for the human TGT homology model. It has already been reported that the 
Val233/Gly216 and Cys158/Val145 replacements are highly conserved among the 
bacterial and eukaryotic domains [25], respectively. Taking into account the 
newly deposited sequences in a multiple sequence alignment of 100 
bacterial, and 100 eukaryotic TGT sequences, Val233 is found to be strictly 
conserved among bacteria, while Gly216 is to 79 % present in eukaryotes. The 
conservation of Cys158 (99 %) in bacterial, and also of Val145 (59 %) in             
q 
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Figure 12: Homology modeling. 
a) Z. mobilis  TGT crystal structure 1ozq (green) in complex with the substrate preQ1 
(orange), showing amino acids of the active site, and a schematic representation of the 
active site. b) Homology model for human TGT (grey) superimposed with the substrate 
preQ1 (orange) from 1ozq, showing amino acids of the active site, and a schematic 
representation of the active site. c) Comparison of the active sites’ solvent accessible 
surfaces of Z. mobilis  TGT (green) and homology model for human TGT (grey). 
a)          
b)          
c)          
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eukaryotic TGTs is sufficiently high to consider these two sites as 
characteristic for the respective domains (chapter 5.2.2, Appendix). Both 
sites were therefore chosen for a mutational study, in order to generate a 
model for the human TGT binding pocket based on the well established 
Z. mobilis TGT system. The mutated bacterial TGT was expected to 
accommodate queuine and to give new insights into the substrate 
recognition properties of human TGT. 
4.2.2 Construction and enzymatic characterisation of Z. mobilis  TGT 
variants 
Z. mobilis  TGT, serving as the basis for this mutational study, exhibits one 
residue within the active site, that is unique among bacteria: Tyr106. Usually, 
at the corresponding position a phenylalanine is found in nearly all bacterial 
TGTs. With 99 % it is very highly conserved. Brenk et al. had already shown, 
that a Tyr106Phe TGT variant exhibits no significant changes of the enzymatic 
properties [14]. In eukaryotic TGTs a phenylalanine at the corresponding 
position (Phe93 in human TGT) is as well conserved to 65 %. Thus, to generate 
a model system as authentic as possbile, the Z. mobilis tgt gene, already 
carrying the Tyr106Phe mutation, was chosen as template for site-directed 
mutagenesis. Since the Tyr106Phe replacement does not affect the enzyme’s 
properties [14], in the following, this mutation as it is considered in all 
studies will not be mentioned explicitly. 
To study the significance of residues Cys158 (Val145 in human TGT) and Val233 
(Gly216 in human TGT) with respect to substrate specificity, a Cys158Val 
variant (named TGT(C158V) in the following), a Val233Gly variant (named 
TGT(V233G) in the following), and a Cys158Val/Val233Gly variant (named 
TGT(C158V/V233G) in the following) were created by site-directed mutagenesis 
of the tgt-Y106F template. All different variants could be produced and 
purified according to standard protocols [12,36]. 
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Subsequently, to be able to compare the enzymatic properties of the variants 
with the wild-type enzyme, kinetic measurements were performed by means 
of a well established assay detecting the incorporation of [8-3H ]-guanine in 
exchange with the native guanine34 from the tRNA substrate. All variants 
were active at the level of detection. While the KM values for guanine and 
tRNA remained almost unchanged within the experimental error (Table 9, 
p. 77), kcat was significantly decreased in all variants compared to the wild-
type enzyme. In case of the TGT(C158V) variant, the turnover number was 
decreased by factors of 3-5, while in case of the TGT(V233G) variant it was 
decreased by a factor of about one order of magnitude, and by almost two 
orders of magnitude for TGT(C158V/V233G).  
Surprisingly, all exchanged residues, which are fairly distant from the 
catalytic residue Asp280 (Figure 12, p. 74), seem to take a dramatic influence 
on the catalytic activity, even though affinity towards the substrates remains 
almost unchanged.  
A further comparison of the human and bacterial TGT binding pockets 
(Figure 12, p. 74) reveals a third residue, which is as well quite proximate to 
the substrate and differs in the two TGTs: Ala232 (Z. mobilis numbering) is 
indeed not strictly conserved (63 %) among bacteria. In about 37 % of the 
remaining cases Ser232 is found which corresponds to Ser216 in the human 
TGT. In eukaryotes this residue is conserved to 51 %. Thus, to exmanine, 
whether this residue is required by an enlarged binding pocket for efficient 
enzyme activity, two additional variants were generated: TGT(A232S/V233G), 
and TGT(C158V/A232S/V233G). Kinetic characterisation of the newly generated 
variants revealed, however, that the Ala232Ser exchange has no significant 
influence on catalytic activity (Table 9). 
Next, incorporation of preQ1 and queuine into tRNA was analysed. Currently, 
no radio-labelled preQ1 and queuine are commercially available. Thus, a 
‘reverse assay strategy’ as already described previously [16,37] was 
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performed. There, the decrease of radioactivity in [8-3H ]-guanine34-tRNA is 
monitored in consequence of the replacement of the labeled guanine by the 
respective substrate. 
 
Table 9: Kinetic charcteriation of the TGT variants. 
wild-type TGT tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 0.9 ± 0.20 1.2 ± 0.20 0.9 ± 0.10 
kcat [10-3 s-1] ** 53.6 ± 0.10 55.8 ± 0.04 106.0 ± 2.72 
kcat/KM [10-3 M-1 s-1] 59.6 46.5 117.8 
    
TGT(C158V) tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 2.1 ± 0.15 1.4 ± 0.15 16.0 ± 2.35 
kcat [10-3 s-1] ** 10.2 ± 0.24 17.6 ± 0.20 35.0 ± 0.82 
kcat/KM [10-3 M-1s-1] 4.9 12.6 2.2 
    
TGT(V233G) tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 2.0 ± 0.32 1.0 ± 0.22 2.1 ± 0.33 
kcat [10-3 s-1] ** 5.4 ± 0.28 4.6 ± 0.24 32.6 ± 1.12 
kcat/KM [10-3 M-1s-1] 2.7 4.6 15.5 
    
TGT(A232S/V233G) tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 2.0 ± 0.24 1.7 ± 0.11 n.d. 
kcat [10-3 s-1] ** 2.2 ± 0.08 5.6 ± 0.10 n.d. 
kcat/KM [10-3 M-1s-1] 1.1 3.3 - 
    
TGT(C158V/V233G) tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 1.4 ± 0.44 2.7 ± 0.32 n.d. 
kcat [10-3 s-1] ** 0.8 ± 0.08 0.6 ± 0.01 n.d. 
kcat/KM [10-3 M-1s-1] 0.6 0.2 - 
    
TGT(C158V/A232S/V233G) tRNATyr * [8-3H ]-guanine preQ1 
KM [M] 0.3 ± 0.04 4.2 ± 0.76 n.d. 
kcat [10-3 s-1] ** 0.2 ± 0.01 0.4 ± 0.01 n.d. 
kcat/KM [10-3 M-1s-1] 0.7 0.1 - 
Wild-type TGT and variants characterised with substrates tRNATyr, [8-3H ]-guanine, and 
[8-3H ]-guanine34-tRNATyr, respectively. * 2nd substrate: [8-3H ]-guanine, ** taking into 
account the presence of TGT as a homodimer able to bind only one tRNA molecule at a 
time [38]. 
KM values for preQ1 could only be determined for the wild-type enzyme and 
the variants TGT(V233G) and TGT(C158V). Data from literature [16] are 
perfectly reproduced for the wild-type enzyme by finding a KM(preQ1) of 
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0.9 M, which approximately corresponds to the KM(guanine) value, and a kcat 
twice as high compared to the [8-3H ]-guanine incorporation. In case of 
TGT(C158V), the KM value for preQ1 increases by a factor of almost 20 with 
respect to the wild-type TGT, although the Cys158Val replacement hardly 
influences the KM(guanine) value. The kcat value is slightly decreased by a 
factor of 3 in comparison to the wild-type enzyme, which is analogously 
observed in the guanine measurements. KM(preQ1) for TGT(V233G) does not 
significantly increase. Hence, the Val233Gly replacement seemed to have no 
dramatic influence on substrate affinities. Furthermore, the kcat(preQ1) value 
is only slightly decreased by a factor of 3 with respect to the wild-type 
enzyme. 
The reverse ‘washout assay’, where [8-3H ]-guanine is excorporated from 
tRNA, implicates a considerably lower signal to noise ratio compared to the 
basic assay, where the incorporation of [8-3H ]-guanine into tRNA is 
monitored. In combination with the dramatically reduced turnover number of 
the TGT(C158V/(A232S)/V233G) variants, the decrease of radioactivity per time 
intervall is not sufficient for an accurate determination of Michaelis-Menten 
parameters. The amount of enzyme used in the assay cannot be further 
elevated to obtain a better signal, since an excess of substrate has to be 
assured. 
In case of queuine, for the variants TGT(V233G), and TGT(A232S/V233G), only 
very high queuine concentrations (30 - 500 M) lead to a detectable decrease 
of the radioactive signal due to the excorporation of [8-3H ]-guanine. 
However, even at a concentration of 10 mM queuine, the remaining variants 
TGT(C158V), TGT(C158V/V233G) and TGT(C158V/A232S/V233G) are not able to 
excoporate [8-3H ]-guanine (Figure 13).  
Suprisingly, in the control reaction, for the wild-type enzyme an even faster 
decrease of the radioactive signal is observed, indicating, that the wild-type 
enzyme is obviously able to accept queuine as a substrate. In conclusion, all 
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variants with the Cys158Val exchange seem to be unable to excorporate 
[8-3H ]-guanine in the presence of queuine as substrate.  
Figure 13: Excorporation of [8-3H ]-guanine from labelled tRNATyr in the presence of 
queuine. 
 
4.2.3 Crystal structures 
To study the constructed human TGT binding pocket model in structural 
terms, two variants were crystallised. The TGT(V233G) variant, representing 
the assumed minimal requirement to generate an enlarged binding pocket 
for queuine accommodation, as well as the TGT(C158V/A232S/V233G) variant, 
representing the binding pocket, probably most similar to the human TGT 
binding pocket, were selected for this purpose. Besides the uncomplexed 
proteins, also preQ1- and queuine-complexed structures were studied for 
these variants and will be described in the following. 
The superposition of the apo-structures of TGT(V233G) and TGT(C158V/ 
A232S/V233G) with wild-type TGT (Figure 14a) shows, as expected, that the 
backbones adopt identical conformations. In addition, there is a dramatic        
f 
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Figure 14: Uncomplexed (apo) TGT(V233G) and TGT(C158V/A232S/V233G) crystal structures. 
a) TGT(V233G) (blue, 2.25 Å resolution, left), and TGT(C158V/A232S/V233G) (red, 1.60 Å 
resolution, right) apo structures, superimposed with wild-type TGT (green, PDB code 
1pud). 
b) 2|Fo|-|Fc| density contoured at a σ level of 1.5 is coloured blue. TGT(V233G) (blue, 
left), and TGT(C158V/A232S/V233G) (red, right) binding pockets, respectively. 
a)     
b)    
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gain of space inside the binding pocket due to the amino acid replacements, 
especially of Val233Gly. The generated space is occupied by well-defined 
water molecules (Figure 14b).  
In case of the TGT(V233G) variant, the exchanged residue Val233Gly is only 
poorly defined. For the Cys158 side chain a double conformation is observed. 
In general, the B-factors in the region next to this residue are relatively high 
in all deposited TGT structures (~ 55 Å2), compared to other active site 
residues. In addition, there are two other TGT variant structures, exhibiting a 
double conformation of the Cys158 side chain: 1pxg (a Asp280Glu variant in 
complex with preQ1, and 1ozq (a Tyr106Phe variant in complex with preQ1). 
Figure 15: preQ1 bound TGT(V233G) and TGT(C158V/A232S/V233G) crystal structures. 
a) TGT(V233G) is represented in blue, 2|Fo|-|Fc| density contoured at a σ level of 1.5 is 
coloured blue, |Fo|-|Fc| density contoured at σ a level of 3 is coloured green (1.19 Å 
resolution). 
b) TGT(C158V/A232S/V233G) is represented 
in red. 2|Fo|-|Fc| density contoured at a 
σ level of 1.5 is coloured blue, |Fo|-|Fc| 
density contoured at σ a level of 3 is 
coloured green (1.46 Å resolution). 
c) Solvent accessible surface represen-
tation of the TGT(C158V/A232S/V233G) 
binding pocket, showing electron 
densities of the ligand and water 
molecules. 
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Nevertheless, in case of the TGT(C158V/A232S/V233G) variant, all exchanged 
residues show well-defined electron density (Figure 14b). 
The preQ1 complex structures of the two variants show, as expected, an 
analogous binding mode of the ligand (Figure 15). The protein backbone 
superimposes almost perfectly. However, the high B-factors of preQ1 in the 
TGT(V233G) variant binding pocket indicate, that the ligand is probably not 
fully occupied. Again, the Gly233 density is relatively weak and the Cys158 side 
chain was refined with a double conformation, although the splitting is only 
weakly indicated. In case of the TGT(C158V/A232S/V233G) variant, all 
exchanged residues show well defined electron density (Figure 15b). The 
newly created subpocket is occupied by well-defined water molecules (Figure 
15c), most of them at similar positions compared to the apo structures. 
In case of queuine, co-crystallised with the TGT(V233G) variant, partial density 
corresponding to the purine heterocycle could be assigned. However, 
attempts to refine the position of the heterocycle did not reveal conclusive 
results. Obviously, the ligand shows only minor population or extended 
disorder in the binding pocket making any refinement of its posistion 
unreasonable. 
Figure 16: Crystal structure of TGT(C158V/A232S/V233G) co-crystallised with queuine.  
a) 2|Fo|-|Fc| density contoured at a σ level of 1.5 is coloured blue, |Fo|-|Fc| density 
contoured at σ levels of 3 (left), and 2 (right), respectively, is coloured green (1.60 Å 
resolution). 
b) Queuine, docked into the crystal structure with GOLD [39,40]. Two of the highest 
scored (DrugScoreCSD [41]) docking poses are shown. Favourable per atom contributions 
to the overall score are indicated by blue spheres, while the size of the sphere 
corresponds to the respective contribution, disfavourable per atom contributions are 
indicated by red spheres. 
c) Superposition of the two docking poses of queuine with the crystal structure of 
TGT(C158V/A232S/V233G) in complex with queuine. 
d) Superposition of three active site bound water molecules from the preQ1•TGT(C158V/ 
A232S/V233G) crystal structure (represented as green spheres) with electron density of the 
queuine•TGT(C158V/A232S/V233G) crystal structure. 
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In case of the queuine•TGT(C158V/A232S/V233G) variant complex structure, the 
electron density of the purine heterocycle is well defined. For the 
cyclopentenyl moiety only poorly defined electron density can be observed. 
Comparing the traces of the electron density and its spacial location with 
respect to the apo and preQ1 structures, it appears obvious that the 
remaining rather large difference electron density peak does not originate 
from some bound water molecules, present in the apo or preQ1 structures 
(Figure 16d). Apparently, the enlarged binding pocket does not offer 
appropriate interaction partners for the hydroxyl groups of the cyclopentenyl 
moiety in H-bonding distance. Therefore, it is assumed that the ring adopts 
multiple orientations resulting in a pronounced disorder. Docking queuine 
into this structure using GOLD [39,40] reveals several binding orientations of 
the cyclopentenyl ring. None of them establishes strong interactions to the 
protein (Figure 16b). The two best scored docking solutions overlap in an 
area that nicely coincides with the observed difference electron density peak. 
The latter peak could not be assigned to any of the previously detected water 
molecules in the uncomplexed or preQ1 bound cases (Figure 16d). 
4.2.4 Molecular dynamics simulation 
To probe a possible distribution of the cyclopentenyl moiety over several 
orientations in absence of appropriate interaction partners for directional 
interactions, molecular dynamics (MD) simulations of the complex were 
performed. As starting geometry, the TGT(C158V/A232S/V233G) variant 
structure complexed by queuine was used. To generate a reasonable pose for 
queuine, the ligand was docked into the structure with GOLD [39,40] and 
minimised with the MAB force field in MOLOC [42]. Analysis of the MD 
trajectory revealed that, in fact, the cyclopentenyl moiety shows high residual 
mobility inside the binding pocket (Figure 17a). Two snapshots were 
extracted from the simulation, and superimposed based on a Cα fit of all 
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protein residues with the TGT(C158V/A232S/V233G) crystal structure (Figure 
17b). 
Figure 17: MD simulation of TGT(C158V/A232S/V233G) in complex with queuine.  
a) Distance between an atom of the flexible cyclopentenyl moiety and a backbone 
amide nitrogen from a residue, deep inside the new subpocket, measured over the 
MD simulation time. 
b) Two queuine conformers from MD simulation snapshots superimposed with the 
TGT(C158V/A232S/V233G) crystal structure and the electron density. 
a)      
Very similar to the previously described docking study, the region of the 
remaining difference electron density that could not be assigned to water 
molecules, fits nicely with the central part of the cyclopentenyl moiety 
considering two different orientations of queuine during the MD simulation. 
These results support the hypothesis that queuine is bound to the 
TGT(C158V/A232S/V233G) variant. Via its central part, the obviously highly 
flexible cyclopentenyl moiety creates the difference electron density of the 
ligand in this region. 
Additionally, also an MD simulation of the uncomplexed wild-type enzyme 
was performed. Interestingly, also the region between the crucial residues 
(Val233, Cys158) exhibits pronounced flexibility (Figure 18). It possibly creates 
a small subpocket, similar to the one opened in the TGT(C158V/A232S/V233G) 
variant. Moreover, volumes of the different binding pockets were calculated     
.  
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Figure 18: MD simulation of apo wild-type TGT.  
Distance between Val233 Cα and Cys158 Sγ, measured over the MD simulation time. The 
green vertical lines indicate snapshots, that have been extracted for the calculations of 
binding pocket volumes, listed in Table 10. 
 




Wild-type TGT·preQ1 (1p0e) 2.5 
TGT(C158V/A232S/V233G)·queuine 6.5 
hTGT homology model 6.0 
Wild-type TGT (apo), MD snapshot 1.4 ns 7.5 
Wild-type TGT (apo), MD snapshot 2.5 ns 7.1 
Wild-type TGT (apo), MD snapshot 3.5 ns 2.5 
with CASTp [43] as listed in Table 10. The binding pockets of both, the 
TGT(C158V/A232S/V233G) as well as the hTGT homology model, were found to 
possess more than twice as large binding pockets, compared to wild-type 
bacterial TGT. In light of these values it is remarkable to note that the 
binding pocket volume of the wild-type bacterial TGT can significantly open 
up as indicated by some frames during the MD simulation due to the 
mentioned flexibility in the region between the residues Val233 and Cys158. 
The binding pocket then reaches volumes even larger than the eukaryotic 
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TGT binding pocket models, large enough for queuine accomodation (Table 
10). After several nanoseconds, the original state, where the subpocket is 
closed again, is adopted, as indicated by the small volume of the binding 
pocket of the third MD snapshot (Figure 18, Table 10). Therefore, it even 
might be possible that also the wild-type enzyme is able to bind queuine. 
Interestingly in this context, wild-type TGT crystals are destroyed under 
queuine soaking conditions. In case of TGT, such findings often indicate that 
the soaked ligand is able to bind to the active site but requires structural 
adaptation of the enzyme destroying crystal contacts. In agreement with this, 
wild-type TGT was found to be able to excorporate labeled guanine from 
tRNA in the presence of queuine (Figure 13, p. 79). 
4.2.5 Co-crystallisation of the TGT variants with preQ1 derivatives 
To further probe the new, enlarged binding pocket in structural terms, for 
several preQ1 derivatives co-crystallisation trials were attempted with the two 
TGT variants. All selected derivatives, such as a phthalic acid derivative, a 
dimethylformimide derivative, or a t-butyloxycarbonyl (Boc)-protected preQ1 
(Figure 19), were easily available as intermediates or by-products of the 
queuine synthesis. These compounds feature spatial requirements which 
exceed beyond preQ1. In contrast, they resemble, in steric terms, more the 
shape of queuine.  
Figure 19: preQ1 derivatives.  
a) Phthalic acid derivative of preQ1 b) Dimethylformimide derivative of preQ1 
c) Boc-preQ1 d) Queuine. 
a)    b)    c)    d)  
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Co-crystallisation and soaking attempts of the two TGT variants with the 
phthalic acid derivative failed. Rather the exposed microseeding or full size 
crystals were destroyed in the presence of this compound.  
Co-crystallisation trials of the two TGT variants with the dimethyl formimide 
derivative did not yield any bound ligand in the structures.  
Figure 20: Crystal structure of 
Boc-preQ1 bound to the TGT(C158V/ 
A232S/V233G).  
a) 2|Fo|-|Fc| density contoured at a σ 
level of 1.5 is coloured blue, |Fo|-|Fc| 
density contoured at a σ level of 3 is 
coloured green (1.26 Å resolution). 
(1): usual orientation of carbonyl in 
all other deposited TGT structures, 
(2): usual position of the following 
residue 233. b) Steric comparison of 
Boc-preQ1 with queuine. c) Queuine 
docking pose superposed with the 
crystal structure of TGT(C158V/A232S/ 
V233G) in complex with Boc-preQ1. 
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Interestingly, a complex structure of the TGT(C158V/A232S/V233G) variant with 
Boc-protected preQ1 could be determined (in the corresponding trial with the 
TGT(V233G) variant only an unoccupied binding pocket could be observed) 
(Figure 20a). In this complex, the side chain of Ser232 and the loop Gly233-
Gly234 are completely disordered, but the orientation of the Ser232 carbonyl 
group indicates already a different conformation of the loop 232-234, 
compared to all other TGT structures, leading to a probably even larger, and 
‘opened’ binding pocket. Volume comparisons of Boc-preQ1 with queuine 
reveals good steric similarity (Figure 20b). In addition, the observed 
Boc-preQ1 binding conformation superimposes well with the assumed 
queuine binding modes from docking results (Figure 20c). 
In the radioactive ‘washout assay’ the TGT(C158V/A232S/V233G) variant is able 
to excorporate labeled guanine from tRNA in the presence of 10 M 
Boc-preQ1 (chapter 5.3.2f, Appendix). Thus, the enzyme variant seems to be 
able to not only bind but also accept this preQ1 derivative as substrate. 




4.3.1 The turnover numbers of the TGT variants decrease 
dramatically 
In this study it was attempted to modify substrate specificity of bacterial TGT 
towards human TGT to investigate properties of an eukaryotic TGT binding 
pocket by means of a model system. On the basis of a multiple sequence 
alignment and homology modelling, three residues were selected for 
mutation - apart from the Tyr106Phe exchange. The TGT variants, however, 
showed unexpected kinetic behaviour. While KM values for guanine and tRNA 
remained almost unchanged within the experimental error for all variants, 
kcat values were reduced by factors of one to two orders of magnitude in 
several cases.  
These results indicate, that although the mutation sites are rather distant 
from the catalytic residue Asp280, they play a crucial role for efficient enzyme 
turnover rates. As already suggested by Romier et al. [11], residues 233 and 
158 perform van der Waals interactions to the purine heterocycle of the 
substrate. They might be important for stabilisation of the complex during 
catalysis. However, the Cys158 side chain was observed to be not completely 
rigid in the TGT(V233G) variant crystal structures. A possible explanation 
could be that upon Gly233Val replacement an appropriate bulky partner is 
missing to fix the orientation of the cystein side chain. This probably leads to 
the slight increase of the KM value towards preQ1.  
4.3.2 The turnover numbers of TGT variants increase for the 
substrate base preQ1 
For preQ1 kcat values for the different TGT variants are significantly higher. 
The enhancement of kcat for preQ1 incorporation has already been 
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discussed [16,37] and possibly correlates with the nucleophilicity of nitrogen 
N 9 in the respective substrates. In each case nitrogen N 9 nucleophilically 
attacks C 1 of the covalently bound tRNA ribose34 during catalysis. In preQ1, 
this nitrogen is the most potent nucleophile, as it is in no electronic 
conjugation with the exocylic amino methyl group. In guanine, N 9 is less 
nucleophilic due to an electron withdrawing effect of N 7 being in 
conjugation with N 9. This is fully consistent with the observed decrease in 
turnover in the order preQ1 > guanine.  
4.3.3 Increased KM for preQ1 
However, the KM value for preQ1 of the TGT(C158V) variant is drastically 
increased (factor 17.5, Table 9). This loss in binding affinity for preQ1 could 
be due to different van der Waals contacts provided by Val158 replacing 
Cys158. Already the KM values for guanine show a slight tendency to lower 
values, upon Cys158Val exchange (TGT(C158V/V233G) and TGT(C158V/A232S/ 
V233G) variants, Table 9). Only a few eukaryotic TGTs have been kinetically 
characterised in literature: from rat liver [8], rabbit erythrocytes [44], and 
wheat germ [45]. For most of these TGTs no kinetic data concerning preQ1 
were published, except for wheat germ [45], where the authors stated that 
the affinity of TGT towards preQ1 was not exactly determined but found to be 
at least 100-fold reduced in comparison to queuine. Taking into account that 
eukaryotic TGTs have no physiological need to incorporate preQ1 into tRNA, 
as queuine is directly inserted to tRNAs (preQ1 is not a relevant substrate in 
eukaryotes), the affinity loss of preQ1 towards the TGT variants constructed 
in this study suggests another eukaryotic TGT specific property. Here, the 
affinity loss observed for the purine heterocycle moiety could possibly be 
compensated in the actual substrate queuine by additional hydrophobic 
interactions of Val158 with the cyclopentenyl moiety. This was already 
suggested by Romier et al. [11]. Furthermore, additional hydrogen bonds 
could be formed between the hydroxyl groups of the cyclopentenyl moiety 
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and the protein. This study did not reveal any favourable interaction partners 
for these hydroxyl groups, and the cyclopentenyl moiety remains disordered 
in the co-crystal structure. However, a reconsideration of the homology 
model and the multiple sequence alignment suggests another residue to be 
exchanged to better approximate human TGT: Tyr161 (Z. mobilis numering)/ 
Ser148 (H. sapiens numbering). This residue was not considered in the first 
attempt, since it is quite distant from the substrate binding pocket in the 
bacterial wild-type TGT binding pocket. It points towards the surface on the 
back side of the protein. In bacterial TGTs to 75 % tyrosine or phenylalanine 
is found at this position. In eukaryotic TGTs in 50 % threonine or serine (as in 
H. sapiens TGT) is present, potentially featuring a hydrogen bond towards 
one of the hydroxyl groups as shown in Figure 21. Queuine was docked into 
the human TGT homology model using GOLD [39,40] and minimised in the 
MAB force field of MOLOC [42], leaving only the ligand and the binding sites 
residues (Asp89, Phe93, Asp143, Val145, Ser148) flexible. During minimisation, 
the Ser148 side chain rotates towards queuine by about 30 °. Also the MD 
simulation of the complex structure revealed a limited number of interaction 
sites for the cyclopentenyl moiety of queuine inside the chimeric model 
binding pocket. Creating an additional interaction site by the Tyr161Ser 
exchange could fix queuine in the binding pocket. 
Figure 21: Queuine docked into the hTGT homology 
model after minimisation with the MAB force field of 
MOLOC [42].  
The GOLD [39,40] docking pose was scored with the 
knowledge-based scoring function DrugScoreCSD[41]. 
Favourable per atom contributions are indicated by 
blue spheres, while the size of the sphere 
corresponds to the score, disfavourable per atom 
contributions are indicated by red spheres. 
Characterisation of a model system for the human TGT binding pocket 93 
 
4.3.4 Z. mobilis wild-type TGT is eventually able to bind queuine 
Surprisingly, in the radioactive ‘washout assay’, the wild-type enzyme 
showed an excorporation of [8-3H ]-guanine in the presence of queuine. 
Okada et al. [21] reported that E. coli TGT is unable to accept queuine as a 
substrate. In their assay 50 nM [14C]-guanine34-tRNATyr were incubated with 
217 nM E. coli TGT and 7.5 M queuine. Already at this concentration, an 
excorporation of about 10 % of radioactivity is noticeable (Figure 22). In the 
present study, a concentration of 500 M led to an even higher amount of 
radioactivity excorporation (Figure 13, p. 79).  
Figure 22: Okada et al. [21], Figure 2.  
 
However, these indirect assays only show that the presence of queuine leads 
to the excorporation of labeled guanine from tRNA. Thus, it is only cautiously 
assumed but not proven that it is queuine that is incorporated into tRNA in 
exchange. In this study, also MALDI-TOF/MS analyses of a RNA oligoAsp 
product of the TGT catalysed reaction were performed. The aim was to record 
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the base incorporated into tRNA by the enzyme. The results are listed in 
chapter 4.5 but will not be discussed here, since they did not allow a 
conclusive interpretation free of any contradictions.  
Nevertheless, binding of queuine to wild-type Z. mobilis TGT seems not to 
be impossible: wild-type TGT crystals soaked with queuine immediately 
dissolved, possibly indicating a binding of queuine to the enzyme. In 
addition, MD simulations of the wild-type apo structure revealed a flexibility 
of the region around residues 158 and 233, possibly enabling a binding of 
queuine between these residues (Figure 18, Table 10, p. 86). Finally, the 
radioactive ‘washout assay’ clearly showed excorporation of [8-3H ]-guanine 
in the presence of queuine. 
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4.3.5 Outlook 
In the future, a new crystallisation screen for the wild-type TGT in complex 
with queuine should be performed to determine the complex structure, or to 
reveal, what kind of compound is bound to the enzyme. 
The variant crystals could be soaked with the cyclopentenyl moiety or other 
small molecule fragments in addition to preQ1, to assess, whether they are 
able to bind to the generated subpocket. The variants are only models of a 
eukaryotic TGT binding pocket and possibly do not provide the cyclopentenyl 
moiety’s interaction partners in appropriate distances. Eventually, in a free 
(not preQ1-associated form), the cyclopentenyl moiety is able to adopt a 
better orientation leading to a better interaction pattern towards the binding 
pocket of the models. Finally, even though enzymatic characterisation of the 
variants has been proven difficult or even impossible, structural analysis of 
an additional Tyr161Ser variant could be performed, to further probe the 
binding pocket of the model system. However, it has to be considered, that 
amino acid residues further remote from the active site might affect 
indirectly active site residues as previously reported for TGT [16]. This might 
provide a slightly different but significantly better interaction pattern towards 
the queuine cyclopentenyl moiety actually given within an eukaryotic TGT 
binding pocket. 
In conclusion, this study emphasises the importance to characterise the 
original protein structure to evaluate substrate specificity. Even for quite 
similar proteins, the composition of the active site, including remote residues 
taking indirect impact can be different enough to modulate enzymatic 
activity or specificity. There is still much to be learnt about TGTs originating 
from different domains of life that cannot be gleaned from homology 
models. 
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4.4  Summary 
tRNA-guanine transglycosylases (TGT) - present in all three domains of life - 
catalyse a base exchange reaction in tRNAs. In bacteria, the mechanistic 
pathway of the guanine exchange towards the modified base preQ1 is well 
characterised due to crystal structure analyses and elaborate kinetic studies 
of Zymomonas mobilis TGT [11-16]. As TGT plays a key role in pathogenicity 
of Shigella flexneri [26], the causative agent of bacterial dysentery, it has 
been established as a target for structure-based drug design [30]. However, 
eukaryotes also possess a TGT with high homology to the bacterial one and 
most residues inside the binding pocket are conserved [25]. In an analogous 
reaction the base queuine is incorporated into tRNA. Hence, it is of utmost 
importance to study selectivity-determining features. 
Since no crystal structure of an eukaryotic TGT is yet available, in this study 
based on Z. mobilis TGT a genetically engineered human TGT binding pocket 
was designed as a model system. Three amino acids specific for the human 
TGT binding pocket were introduced by site-directed mutagenesis of the 
Z. mobilis TGT gene, (Cys158Val, (Ala232Ser), Val233Gly). After purification, 
kinetic measurements and crystallisation were performed. Modified assays 
showed that - surprisingly – the Z. mobilis TGT variants have dramatically 
slowed down so that kinetic parameters could not be determined for 
incorporation of queuine into tRNA. Nevertheless, crystal structure analysis 
and molecular dynamics simulations indicate a possible binding of queuine 
to the active site of the variants. Additionally, it was observed that the wild-
type enzyme is able to excorporate labeled guanine from tRNA in the 
presence of queuine. MD simulations indicate that the enzyme is able to 
open up a subpocket that potentially could accommodate queuine.  
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4.5 Supplement 
4.5.1 MALDI-TOF/MS analysis of the RNA product 
To record the base incorporated into tRNA by the TGT variants and the wild-
type enzyme, another assay was performed. In this assay the RNA product of 
the reaction was subsequently analysed via Matrix-assisted laser desorption 
ionisation time-of-flight mass spectrometry (MALDI-TOF/MS). However, 
highly charged full length tRNA is not applicable for an accurate MALDI- 
TOF/MS analysis, and secondly, the relative mass difference between native 
and modified tRNA would be too small (Table 11). It is reported that TGT also       
f 
Table 11: Relative mass differences of native and modified RNA substrates. 
RNA mass [Da] ∆mass [%] 
native oligoAsp 6678   
preQ1-oligoAsp 6707 0.43 % 
queuine-oligoAsp 6805 1.90 % 
native tRNATyr 27492   
preQ1-tRNATyr 27521 0.11 % 
queuine-tRNATyr 27619 0.46 % 
Figure 23: MALDI-TOF/MS analysis of native and preQ1-modified RNA oligoAsp. 
a) Sequence and assumed mini-helix structure of the tRNAAsp anticodon stemloop RNA 
oligo, b) MALDI-TOF mass spectrum of unmodified RNA oligoAsp, c) MALDI-TOF mass 
spectrum of preQ1-modified RNA oligoAsp (∆mass to (b): 29 Da). 
a)  b)  c)  
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accepts so-called ‘mini-helices’ [18] as RNA-substrate. Thus, a 21mer RNA 
oligo (corresponding to the tRNAAsp anticodon stemloop) was purchased 
(Figure 23a). First control experiments with the wild-type enzyme and 
500 M preQ1 showed that, in fact, the RNA oligoAsp is accepted as substrate 
and preQ1 is incorporated. This is indicated as native and preQ1-modified 
RNA oligoAsp could be clearly distinguished in the MALDI-TOF mass spectra. 
The observed mass difference corresponds to the expected values (Figure 
23b, c; Table 12). Also lower preQ1 concentrations were tested. Already a 
concentration of 5 M lead to a detectable, but only partial guanine to preQ1 
replacement, while at a concentration of 1 M only unmodified RNA oligoAsp 
can be detected. 
Table 12: MALDI-TOF/MS analysis of RNA oligoAsp reaction products.  
TGT substrate ∆mass1 [Da] 
wild-type TGT preQ1 29 ± 2  
TGT(V233G) preQ1 28 ± 2  
TGT(C158V/V233G) preQ1 28 ± 2(2)  
wild-type TGT queuine 27 ± 2(2)  
TGT(V233G) queuine 27 ± 2(2)  
TGT(C158V) queuine -  
TGT(C158V/V233G) queuine -  
TGT(C158V/A232S/V233G) queuine -  
wild-type TGT Boc-preQ1 38 ± 2(2)  
TGT(V233G) Boc-preQ1 38 ± 2(2)  
TGT(C158V) Boc-preQ1 38 ± 2(2)  
TGT(C158V/V233G) Boc-preQ1 38 ± 2(2)  
TGT(C158V/A232S/V233G) Boc-preQ1 38 ± 2(2)  
1) Mass differences to native oligo (6678 Da): 29 Da would correspond to a preQ1 
modification of the RNA oligoAsp, 127 Da to a queuine modification, 128 Da to a 
Boc-preQ1 modification, 2) Only partial modification observed. 
Also the TGT(V233G) variant (decreased kcat by a factor of about 3 - 10 with 
respect to the wild-type TGT values, Table 9, p. 77) is able to incorporate 
preQ1 efficiently (Table 12), once incubated with 500 M preQ1. It can be 
assumed, that the TGT(C158V) variant (decreased kcat by a factors of about 3 
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with respect to the wild-type TGT values, Table 9, p. 77) is able to 
incorporate preQ1 with similar efficiency, since the (irreversible) exchange 
reaction has been executed for more than 16 h. For such a long time span 
even the increased KM(preQ1) value should not matter significantly. The 
TGT(C158V/V233G) variant (decreased kcat by a factor of about two orders of 
magnitude with respect to the wild-type TGT values, Table 9, p. 77) is found 
to be rather inefficient, thus only a reduced quantity of preQ1 modification is 
detected besides unmodified RNA oligoAsp. In light of this finding it can be 
assumed, that also the TGT(C158V/A232S/V233G) variant with a similarly 
reduced kcat (Table 9, p. 77) is only capable to produce minor amounts of 
preQ1-modified RNA oligoAsp. 
Figure 24: MALDI-TOF/MS analysis of RNA oligoAsp reaction products upon incubation 
with queuine. 
a) MALDI-TOF mass spectrum of partially preQ1-modified RNA oligoAsp, produced by 
wild-type TGT incubated with queuine, b) MALDI-TOF mass spectrum of native 
(unmodified) RNA oligoAsp, produced by TGT(C158V) incubated with queuine. 
a)         b)  
Incubation of the RNA oligoAsp with 500 M pure queuine, results in no 
significant queuine modification. In case of TGT(C158V), TGT(C158V/V233G), 
TGT(C158V/A232S/V233G) only unmodified RNA oligoAsp could be isolated 
(Figure 24b). These results are in good agreement with the radioactive 
‘washout assay’, where these three variants were found to be not sufficiently 
active to produce a measurable signal. However, in case of the remaining 
TGT(V233G) variant and the wild-type enzyme, the mass spectra showed 
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surprising results. A signal with a mass difference is observed, that suggests 
incorporation of preQ1 (Figure 24a; Table 12, p. 98). Contamination of 
queuine by preQ1 can be excluded as high pressure liquid chromatography 
coupled with electrospray ionisation mass spectrometry1 (HPLC/ESI-MS) and 
1H-NMR spectrum2 analyses did not provide any evidence. In addition, since 
the radioactive ‘washout assay’ suggested also Boc-preQ1 as a substrate, 
RNA oligoAsp products of the corresponding reaction were analysed as well 
(chapter 5.4.j-m, Appendix). The detected peaks do not correspond to any 
expected masses. Rather, it is awkward to interprete the calculated mass 
differences (Table 12, p. 98). Thus, MALDI-TOF/MS analysis of the RNA 
product seems to be not appropriate to determine the base that had been 
incorporated by TGT. 
4.5.2 MALDI-TOF/MS assay drawbacks 
MALDI-TOF/MS analysis of the RNA oligoAsp products obtained after 
incubation with the TGT variants was only successful for those variants, that 
exhibited an only moderately decreased reaction velocity. Due to the 
temperature sensitivity of the RNA oligoAsp substrate, the reaction mixture 
was incubated at 25 °C. To compensate for the probably lower enzymatic 
activity at this temperature, incubation time was elongated to 16 h (in 
comparison, the [8-3H ]-guanine assay which is performed at 37 °C was only 
elongated from 4 min to 30 min to receive a measurable signal of the 
variants). Yet, there are additional difficulties. Curnow et al. [18] reported a 
6-fold increase of KM for a 17-base tRNATyr anticodon stemloop. For wild-
type TGT only a rough estimation of the KM value for the RNA oligoAsp 
substrate could be performed via Lineweaver-Burk linear regression of 
[8-3H ]-guanine assay data (chapter 5.3.1f, Appendix). Already for the wild-
____________________________________________________________ 
1) Performed by Anja Vogt, Institut für Pharmazeutische Chemie, Philipps-Universität Marburg. 
2) Performed by Hans-Dieter Gerber, Institut für Pharmazeutische Chemie, Philipps-Universität 
Marburg. 
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type enzyme, the approximate KM with 1.5 mM is quite high. For the even 
less active variants, assuming no further increase of the KM, the catalytic 
efficiency would be by far too low to record detectable modification of the 
RNA oligoAsp. Curnow et al. [18] reported that a 4-base elongation of their 
minihelix led to a stemloop that is stable at 37 °C. This could be a possibility 
to increase the performance of the less active variants, eventually leading to 
a detectable modification of the RNA oligoAsp. Nevertheless, the conditions 
applied during MALDI-TOF/MS analysis of the RNA oligoAsp have to be 
examined first. The results described above cannot be interpreted 
consistently but they might indicate that the stability of the base 
modification is not sufficient to survive the applied conditions in the MALDI-
TOF/MS experiments.  
In literature, analysis of tRNATyr RNase T1 hydrolysis by PEI-cellulose 
chromatography had revealed the position of modification in tRNA [21], and 
tRNA modification with CNBr and RPC-5 analysis could distinguish between 
native and queuine modified tRNAs [46-48]. These techniques could possibly 
support the analysis of full length tRNA after incubation with the TGT 
variants. 
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4.6 Materials and Methods 
4.6.1 Homolgy modelling 
Amino acid sequences were extracted from the deposited crystal structures 
with PDB codes: 1r5y (chain A), 1y5v (chain A), 1y5w (chain A), 1ozm (chain 
A), 1ozq (chain A), and 1q2r (chain A, and B, respectively). These sequences 
were aligned with the human TGT sequence (from SWISS-PROT 
Release 54.3 [49]) utilising Clustal W 1.83 [33]. The sequences aligned with 
41 -42 % identity. Based on the alignment, ten homology models for human 
TGT were calculated with MODELLER 6a [35]. The best model (model no. 8) 
was selected by picking the model with the lowest value (11,429.19) of the 
MODELLER objective function, which is reported in the second line of the 
model PDB file. 
4.6.2 Construction of the TGT mutants C158V, V233G, C158V-
V233G, A232S-V233G, C158V-A232S-V233G 
Site-directed mutagenesis was performed using the QuickChangeTM kit 
(Stratagene) following the vendor’s protocol. The oligonucleotides listed in 
Table 13 were used to introduce the mutations into the Y106F mutant of the 
tgt gene on the expression plasmid pET9d-ZM-Y106F [14]. Sequencing of 
the entire tgt gene (MWG Biotech, Ebersberg) confirmed the presence of the 
desired mutations as well as the absence of any further unwanted mutation. 
Subsequently, the mutated plasmids were transformed into E. coli BL21 (DE3) 
pLysS cells. 
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Table 13: Oligonucleotides used in mutagenesis. 
mutation site/ 
oligo name 
sequence (5' to 3')1 
C158V-f 5'-GTA ATG GCC TTT GAC GAA GTC ACG CCT TAT CCA GC-3' 
C158V-b 5'-GC TGG ATA AGG CGT GAC TTC GTC AAA GGC CAT TAC-3' 
V233G-f 5'-GCT GTT GGG GGA TTG GCT GGG GGT GAA GGA CAG GAT G-3' 
V233G-b 5'-C ATC CTG TCC TTC ACC CCC AGC CAA TCC CCC AAC AGC-3' 
A232S-V233G-f 5'-GCT GTT GGG GGA TTG TCT GGG GGT GAA GGA CAG GAT G-3' 
A232S-V233G-b 5'-C ATC CTG TCC TTC ACC CCC AGA CAA TCC CCC AAC AGC-3' 
1) The mutated bases are printed ind bold letters and highlighted with grey background. 
4.6.3 Expression, Purification 
Z. mobilis TGT variants were prepared as described elsewhere [12,36]. E. coli 
tRNATyr (ECY2) was prepared as described by Curnow et al. [50]. Radio-
labeling of tRNATyr was performed as already described [16]. 
4.6.4 Determination of kinetic parameters 
Kinetic parameters for the TGT variants were determined for the different 
substrates essentially as described by Meyer et al. [51]. Michaelis-Menten 
parameters for tRNA and guanine were determined monitoring incorporation 
of radioactively labelled guanine into tRNATyr in position 34. Kinetic data for 
both substrates were determined separately in duplicate and average values 
were calculated. Kinetic parameters for guanine were measured using 
150 nM (wild-type, TGT(V233G), TGT(C158V), TGT(A232S/V233G) variants) - 
300 nM (TGT(C158V/V233G), TGT(C158V/A232S/V233G) variants) TGT, 15 M 
unlabelled E. coli tRNATyr, and variable concentrations of [8-3H ]-guanine 
(0.9 Ci/mmol, Hartmann Analytic) in the range of 0.5 – 20 M in buffer 
solution (200 mM HEPES pH 7.3, 20 mM MgCl2, 0.036 % (v/v) Tween 20 
(Roth)). Kinetic parameters for tRNA were measured using 150 nM (wild-type, 
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TGT(V233G), TGT(C158V), TGT(A232S/V233G) variants) - 300 nM (TGT(C158V/ 
V233G), TGT(C158V/A232S/V233G) variants) TGT, 20 M [8-3H ]-guanine, and 
variable concentrations of tRNATyr (0.25 – 15 M). Initial velocities of the base 
exchange reaction in counts per minute were converted to [M/min] using a 
calibration constant derived from liquid scintillation counting of 
[8-3H ]-guanine solutions with variable concentrations. Kinetic parameters 
were determined via regression using GraFit [52]. 
Michaelis-Menten parameters for preQ1 were calculated via monitoring the 
loss of [8-3H ]-guanine from tRNATyr radio-labelled in position 34. Kinetic 
parameters for preQ1 were measured using using 150 nM (wild-type, 
TGT(V233G), TGT(C158V), TGT(A232S/V233G) variants) - 300 nM (TGT(C158V/ 
V233G), TGT(C158V/A232S/V233G) variants) TGT and 8 M radio-labelled 
tRNATyr. The concentration of preQ1 was varied in ranges of 0.5 – 15 M, 1 –
 50 M, and 25 – 750 M, respectively. Initial velocities in counts per minute 
were calculated from the decreasing tritium labelling level of tRNA due to the 
incorporation of the respective substrate bases. Initial velocities in counts per 
minute were converted to [M/min] using a calibration constant derived from 
liquid scintillation counting of guanine/ [8-3H ]-guanine solutions with 
variable concentrations. Kinetic parameters were determined via regression 
using GraFit [52]. 
4.6.5 MALDI-TOF/MS analysis 
342 pmol of the RNA oligoAsp were incubated with 1.78 M TGT, 1 - 500 M 
preQ1 or queuine in 200 mM HEPES, pH 7.3, 20 mM MgCl2 at 25 °C for at 
least 16 h. TGT and free preQ1 or queuine were extracted from the reaction 
mixture by the addition of equal volumes of Roti-Phenol (Roth) and 
chloroform : isoamylalcohol (24:1). The aqueous supernatant was once more 
treated with an equal volume of chloroform : isoamylalcohol (24:1). An 
additional purification step was performed via gel filtration using NAP-
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columns (GE Healthcare, Life Science). The RNA oligo was eluted with pure 
nuclease-free water and vacuum dried. The samples were further purified 
utilising magnetic beads and analysed by MALDI-TOF/MS by Dr. Silke Seeber 
and Nico Vogel (Institut für Biochemie, Friedrich-Alexander-Universität 
Erlangen- Nürnberg). 
4.6.6 Crystallisation, data collection, and processing 
Recombinant Z. mobilis TGT was expressed in E. coli BL21 (DE3), purified and 
crystallised as described previously [12,36]. TGT variant crystals suitable for 
ligand soaking were produced in a two step procedure. Droplets were 
prepared by mixing 2 l of concentrated protein solution (14 mg/ml) with 
2 l reservoir solution [100 mM Tris/HCl, pH 8.5, 1 mM DTT, 13 % (w/v) 
PEG 8,000, 10 % (v/v) DMSO]. Micro-crystals were grown at 291 K using the 
hanging-drop vapour diffusion method in the presence of 1.0 ml of reservoir 
solution of the respective seeding buffer. Micro crystals grew within two 
weeks. 
Subsequently, macro-seeding was performed under similar conditions to 
obtain crystals of the uncomplexed protein. Again droplets were prepared by 
mixing 2 l of concentrated protein solution with 2 l macro-seeding 
reservoir solution [100 mM Tris/HCl, pH 8.5, 1 mM DTT, 5 % (w/v) 
PEG 8,000, 10 % (v/v) DMSO]. One micro-crystal was transferred into this 
solution. Single crystals with a size of approximately 0.7 x 0.7 x 0.2 mm3 
grew within two to four weeks. 
To allow co-crystallisation of the TGT variants in complex with queuine the 
compound was dissolved in DMSO and added to the macro-seeding droplet 
to a final concentration of 1 to 20 mM. Crystals of the TGT variants 
complexed to preQ1 were produced by a soaking procedure. The compound 
was dissolved in DMSO and added to 2 l of a crystallisation droplet to a final 
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concentration of 10 to 20 mM. Finally, a single TGT crystal was transferred 
into the droplet and soaked for 30 min. 
For data collection, crystals were cryoprotected using glycerol. The glycerol 
and PEG 8,000 concentrations of the macro-seeding buffers were increased 
stepwise by transferring the crystals to six different 2 l cryo-droplets each 
with 5 to 30 min incubation times [glycerol concentrations (v/v): 5 % → 10 % 
→ 15 % → 20 % → 25 % → 30 %; and PEG 8,000 concentrations (w/v): 5.0 % → 
6.3 % → 7.5 % → 8.0 % → 8.8 % → 9.8 %, respectively]. These droplets also 
contained the ligands at equivalent concentrations compared to soaking and 
co-crystallisation conditions. The cryo-soaked crystals were flash-frozen in 
liquid N2. Data sets were collected at cryo conditions (100 K) at the BESSY 
(Berliner Elektronenspeicherring-Gesellschaft für Synchrotronstrahlung, 
Berlin, Germany), PSF (Proteinstrukturfabrik) beamline BL-14.2 and with CuKα 
radiation (λ = 1.5418 Å) using a Rigaku RU-300 rotating-anode generator at 
50 kV and 90 mA equipped with Xenocs focussing optics and an R-AXIS IV 
detector. All crystals tested exhibited monoclinic symmetry in space group 
C2 containing one monomer per asymmetric unit with Matthews coefficients 
of 2.3 - 2.4. Data processing and scaling was performed using the HKL2000 
package [53]. For all refined structures unit cell dimensions for the crystals, 
data collection and processing statistics are given in Table 14. 
Coordinates of the apo TGT crystal structure grown at pH 8.5 (PDB-code: 
1pud) were slightly modified (deletion of coordinates at the mutation sites) 
before applying for initial rigid-body refinement of the protein molecule 
followed by repeated cycles of conjugate gradient energy minimisation, 
simulated annealing and B-factor refinement using the CNS program 
package [54]. Refinement at the later stages for all structures was performed 
with SHELXL [55]. Here, up to 50 cycles of conjugate gradient minimisation 
were performed with default restraints on bonding geometry and B-values: 
5 % of all data were used for Rfree calculation. Amino acid side chains were fit 
to σA-weighted 2|Fo|-|Fc| and |Fo|-|Fc| electron density maps using 
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Coot [56]. Water, glycerol molecules, and ligands were located in the 
difference electron density and added to the model for further refinement 
cycles. Anisotropic conjugate gradient refinement resulted in a significant 
improvement of the models built for 2nso, 2nqz, 3bld, 3bll. During the last 
refinement cycles, riding H-atoms were introduced for the protein residues 
(not for the ligand) without using additional parameters. All final models 
were validated using PROCHECK [57]. Data refinement statistics are given in 
Table 14. 
Table 14: Crystallographic table. 
a) number in parentheses is for highest resolution shell 
b) R(I)sym = Σ |I - 〈I〉| / ΣI with I representing the observed intensities and 〈I〉 
representing the mean observed intensity 
c) Rwork = Σhkl |Fo - Fc| / Σhkl |Fo|. 
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4.6.7 Molecular Dynamics Simulation 
The MD simulation and all setup steps were performed with the Amber 8.0 
suite of programs using the Amber 1999 force field [58]. The 
TGT(C158V/A232S/V233G) variant queuine complex structure was used as 
starting coordinates. The ligand and all crystallographic water molecules 
were removed. Queuine was docked into the structure using GOLD [39,40] 
and minimised in the MAB force field of MOLOC [42], defining only the 
queuine atoms as flexible, while protein atoms were left rigid. For the apo 
wild-type structure simulation, 1pud was used. Missing residues and side 
chains were added and minimised with the Amber 1999 force field. After 
estimating protonation states of all histidines by visual inspection of 
interactions, histidines were set to the appropriate form (double protonated: 
‘HIP’/ protonated at Nδ: ‘HID’ (HIS#: 73, 257, 319, 332, 333)/ protonated at 
Nε: ‘HIE’ (HIS#: 90, 127, 133, 145, 349)). Cysteins coordinating the Zn2+ ion 
were set to ‘CYM’ (CYS#: 319, 320, 323). Hydrogen atoms were added with 
PROTONATE. The protein was initially subjected to 200 steps of minimisation 
using a generalised Born solvation model. Subsequently, the systems were 
solvated in a box of 2563 (TGT(C158V/A232S/V233G)·queuine complex)/ 2350 
(apo wild-type TGT) TIP3P water molecules [59], and two (TGT(C158V/A232S/ 
V233G)·queuine complex)/ three (apo wild-type TGT) sodium ions were added 
to ensure neutrality. After 200 steps of minimisation of the solvated systems, 
the MD simulations were started by heating the solvent to 300 K over a 
period of 20 ps and cooling to 100 K over 5 ps, keeping the protein fixed. 
Then the entire system was brought to 300 K over a period of 25 ps and the 
simulation was carried on for 5 ns under NPT conditions, using a time step of 
2 fs and PME [60] for evaluating the electrostatic interactions. Energy data 
were saved every 20 fs, protein coordinates every 0.5 ps. CARNAL was used 
for further analysis of the trajectory and VMD 1.8.2 [61] for visualisation. 
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4.6.8 Alignment and Figures 
Alignment of structures with similar or identical sequences was performed 
with the alignment function implemented in Pymol (http://www.pymol.org). 
Figures were prepared using Isis Draw (MDL, San Leandro, USA) and Pymol. 
4.6.9 Protein Data Bank Accession Codes 
The following Protein Data Bank (PDB) accession codes were allocated to the 
crystal structures determined during this work: 2nso, 2nqz, 3bl3, 3bld, 3bll, 
3blo (also given in Table 14). 
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5.1 X-ray refinement Toolkit - Manual 
This toolkit is a python [1] based script set, written to assist the setup of 
X-ray refinement cycles. The respective scripts extract all necessary values 
from log files, subsequently edit input files for the following refinement cycle 
and start the corresponding refinement programs. Afterwards, the new log 
files are checked and several values are extracted and written to a summary 
file (info.txt, File 2, p. 122). The script is adjusted to the refinement 
strategy commonly applied in our group: Data processing should be 
performed with HKL2000 [2], rigid body refinement and simulated annealing 
procedures with cns [3], and refinement with either cns or shelxl [4]. 
Generated electron density maps are converted by the scripts for a direct 
read into coot [5]. This toolkit is currently available under 
/nfs/extern/pub/inhouse/(incoming/) tidten/. 
5.1.1 Arrangement of folders and subfolders 
A short README file describes the usage of the 
toolkit. For proper performance of the toolkit, a 
certain arrangement of folders and subfolders has 
to be maintained (Figure 25). Images of the 
dataset can be stored in any directory. However, 
the HKL2000 processing log file and reflections 
file (scaleui.log, output.sca) have to be available 
under dataset/process/. After having processed 
the dataset, and thus having generated the folder 
dataset/process/, the script make_dir.py can be 
applied to generate the folder dataset/refine/ with its subfolders. 
Figure 25: Folder 





Additionally, the python toolkit files are automatically copied to 
dataset/refine/python/. 
dataset/refine/ contains three subfolders: cns/ (for rigid body refinement 
and simulated annealing procedures performed with cns, and cns refinement 
cycles), shelxl/ (for shelxl refinement cycles), info/ (containing the toolkit 
files in the subfolder python/ and the summary file (info.txt, File 2, p. 122), 
where important information is entered during the usage of the toolkit). 
5.1.2 default.txt 
Before the toolkit is used, several files have to be prepared. The HKL2000 
files (scaleui.log, output.sca) have to be present in dataset/process/ as 
described above. The file default.txt (File 1) provided by the toolkit, has to 
be edited and stored under dataset/refine/info/. In default.txt names of 
files, which are read while the script runs, can be changed if desired. The 
‘short name’ of protein and ligand is used to generate the file names of each 
refinement cycle (e.g. 01-prot-lig.ins). 
File 1: default.txt 
Please change default-file-names here: 
 
CNS: 
pdb-file, coordinates for MR:           start.pdb 
sca-file, HKL2000 output:               output.sca 
log-file, HKL2000:                      scaleui.log 
short name of your protein:             prot 
short name of your ligand:              lig 
 
SHELXL: 
dfx-file, inserted in shelxl-ins-file:    GOL.dfx 
start- and end-aa in refinement-model:    11-383 
seq-file, sequence of your whole protein: prot.seq 
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5.1.3 Ligand restraints (shelxl dfx file) 
A shelxl restraint file for glycerol molecules is provided by the toolkit 
(GOL.dfx). For any other ligand molecules, restraints have to be manually 
generated utilising the shelxpro option [J] and may then be simply 
appended to the GOL.dfx file in dataset/refine/info/python/. 
5.1.4 Protein sequence file 
A file containing the (entire) one letter amino acid sequence of the protein 
has to be present in dataset/refine/info/. This file is used to generate 
additional output files after a shelxl run as described later. Storing the entire 
protein sequence instead of only the refined residues has the advantage that 
during PDB deposition of the final structure, the complete sequence is 
already available. 
5.1.5 start.pdb 
A pdb file containing coordinates for rigid body refinement and simulated 
annealing procedures performed by cns has to be provided under dataset/ 
refine/cns/ and named as declared in default.txt (start.pdb). 
5.1.6 First cns run 
Subsequently, structure solution can be started from dataset/refine/cns/ 
utilising the script cns1.py. This script first requests data collection 
information, such as date of data collection, detector type, exposure time, 
detector distance, oscillation range, radiation wavelength. These values have 
to be declared upon PDB deposition. Thus, correct completion is 




File 2: info.txt 
DATA: 
   --------------------------------------------------------- 
   | date-name:                             070316-vac-boc | 
   |-------------------------------------------------------| 
   | detector      |    t    |  dist.  |  phi    | lambda  | 
   |---------------|---------|---------|---------|---------| 
   |        marccd |  5", 3" |  70,150 | 160-290 | 0.97803 | 
   |-------------------------------------------------------| 
   |                        |  all   | highest |  lowest   | 
   |                        |        |  resol. |  resol.   | 
   |------------------------|--------|---------|-----------| 
   | Rsym                   |  3.7 % |  23.7 % |     3.3 % | 
   |------------------------|--------|---------|-----------| 
   | I/sig                  |     34 |     2.4 |        52 | 
   |------------------------|--------|---------|-----------| 
   | redundancy             |    3.6 |   --    |    --     | 
   |------------------------|--------|---------|-----------| 
   | completeness           | 93.7 % |  92.2 % |    87.9 % | 
   |------------------------|--------|---------|-----------| 
   | mosaicity/resolution   | 0.911° | 1.34 Å  | 20- 3.3 Å | 
   |-------------------------------------------------------| 
   |                  |  tot. no.  |  unique  | rej./excl. | 
   |------------------|------------|----------|------------| 
   | frames           |        500 |    --    |          0 | 
   |------------------|------------|----------|------------| 
   | reflexes         |    1542926 |   300004 |          0 | 
   |-------------------------------------------------------| 
   | cell/SpGr | a:    89.949 | b:   64.849 | c:    70.471 | 
   |-----------|--------------|-------------|--------------| 
   |        C2 | alpha:  90.0 | beta: 95.56 | gamma:  90.0 | 





   --------------------------------------------- 
   | Name (cns)    | Rfree   | Rwork   |   ∆R  | 
   |---------------|---------|---------|-------| 
   |    00-vac-boc | 26.84 % | 26.46 % | 0.4 % | 
   --------------------------------------------- 
################################################## 
   ---------------------------------------- 
   | Name (shelxl) | ANIS? | HFIX? | WGHT | 
   |---------------|-------|-------|------| 
   |    01-vac-boc | False |  True |  0.1 | 
   |--------------------------------------| 
   | Cycles   | aa      | HOH | GOL | LIG | 
   |----------|---------|-----|-----|-----| 
   |       50 |  11-383 |   0 |   0 |   2 | 
   |--------------------------------------| 
   | double conf:  9 | ALA: 35 | gaps: 39 | 
   |--------------------------------------| 
   | shelxl           | Rfree   | R1      | 
   |------------------|---------|---------| 
   | Fo > 4sig(Fo)    | 28.09 % | 24.36 % | 
   |------------------|---------|---------| 
   | all,  ∆R: 3.4 %  | 28.37 % | 24.96 % | 
   |------------------|---------|---------| 
   | ratio/merge      |  0.9921 | 25.01 % | 




the radiation wavelength, which is essentially required and inserted into 
input files later on. Thereafter, processing data, such as Rsym, I/σ, resolution, 
number of reflections, unit cell, are extracted from HKL2000 files and written 
to the summary file (info.txt, File 2, p. 122) in dataset/refine/info/.  
Before cns runs are started by the script, the corresponding input files 
(make_cv.inp, generate.inp, rigid.inp, refine.inp) are edited according to 
the previously extracted information. Additionally, the HKL2000 reflection 
file output.sca is copied to the folder dataset/refine/cns/ and converted to 
the cns compatible xpl format. The log files written by the cns runs are read 
and the script is aborted if errors are found, so that manual adjustment of 
input files or others (such as start.pdb) is possible. The subsequent start of 
the script cns1.py then utilises the manually edited cns input file from 
dataset/refine/cns/. cns runs are started in the following sequence: make_cv, 
generate, rigid, refine. After successful cns runs, maps generated by the 
refine run are converted to the coot compatible ccp4 format, Rwork/Rfree 
values are extracted from the log file and written to the summary file 
info.txt. 
In general, the toolkit script suggests default answers (given in brackets 
behind the question), which can be applied by pressing the ‘ENTER’ key. If a 
descision has to be made, the answer given in capitals is defined as the 
default answer (e.g. ‘(y/N)’ means, if only the ‘ENTER’ key is pressed, the 
adopted answer is ‘N’). 
5.1.7 Second and following cns runs 
All following cns runs should be started by the script cns2ff.py. cns2ff.py 
first requests the name of the latest pdb file of the previous coot refinement 
and splits this file into separate pdb files containing protein atoms, ligand 
atoms, ions, water molecules, and glycerol molecules (declared as ‘prosthetic 
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group’), respectively, if present. The cns input files generate.inp, 
minimize.inp, bindividual.inp, water_pick.inp, model_map.inp are edited and 
cns runs are started in the following sequence: generate, minimze(1), 
bindividual, water_pick, minimize(2), model_map (fofc), model_map (3fo2fc). If a 
non-protein, non-water, non-glycerol residue is present, the user is asked to 
decide whether the respective residue should be considered as an ion or as a 
ligand. In the first case, the standard ion restraints are added to the input 
files, while in the second case, the user is asked to provide name and path of 
a restraint file. After successful cns runs, maps are converted to the coot 
compatible ccp4 format, Rwork/Rfree values are extracted from the log file and 
written to the summary file info.txt. 
5.1.8 First shelxl run 
For high resolution datasets, the cns2ff.py script can be skipped, and 
shelxl1.py can be started from dataset/refine/shelxl/. This script first 
copies the last cns refinement pdb file and the reflection file to 
dataset/refine/shelxl/ and generates the shelxl input file (.ins) as well as 
the hkl file (reflections, marked for the calculation of Rfree, which were not 
used during cns refinement are maintained) by utilising shelxpro and a batch 
file. Subsequently, in a separate shell, the generated ins file may be edited 
with the shelxpro option [U], e.g. for the refinement of double conformation 
occupancies or the transformation of water molecule coordinates to the 
nearest symmetry equivalent. Additional command lines may be inserted 
manually as well. If required, also a new ins file can be generated manually 
with the shelxpro option [I], but the file name has to be kept consistently. 
The script is resumed by typing in ‘y’ (“Have you finished? (y)”). In the next 
step, the ins file is edited by the script. The number of refinement cycles is 
changed (CGLS line) according to the user input, and ‘-1’ is added 
automatically to the line for Rfree calculation, ‘ANIS’ for anisotropic refinement 
can be inserted, HFIX restraints can be switched on, and the GOL.dfx 
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restraints file is inserted. The HKLF code is set to 3 (F) per default (since the 
hkl file is generated from the cns .cv file, maintaining the set of reflections 
used for Rfree calculation) but can be changed to 4 (F2), if required. HOPE can 
be switched on and off as desired and the weighting factor (WGHT) can be 
changed from 0.1 (default value) to 0.2 for final refinement cycles. A shelxl 
run is then started by the script, writing a log file automatically. After a 
successful shelxl run, Rwork/Rfree values, as well as the number of refined 
water, ligand and glycerol molecules are written to the summary file 
info.txt. Additionally, the following files are generated: 01-prot-lig.lig, 
01-prot-lig.ala, 01-prot-lig.gap, 01-prot-lig.dbl. The .lig file contains all 
residue names, which are considered as ‘ligand’ (non-protein, non-water, 
non-glycerol. Thus, also ions are counted in the respective field of info.txt 
and listed in the .lig file). The .ala file contains all residue numbers and 
original names, which are present as alanine in the refinement pdb file, but 
have a different side chain according to the sequence file (dataset/refine/ 
info/prot.seq). The .gap file contains all missing residues, according to the 
sequence file, and is used to automatically generate ‘HFIX 33’ lines in the 
next refinement cycle for the N-terminal end of the gap, if required. The .dbl 
file contains all double conformations and their corresponding refined 
occupancies. The respective total numbers of residues in gaps, with double 
conformations, artificial alanines, or ligands are listed as well in the summary 
file info.txt. 
For huge datasets, an analogous shelxh1.py script is available, starting 
shelxh instead of shelxl. Nevertheless, the folder has to be named ‘shelxl’ 
anyway. The default answers differ slightly in shelxh1.py: HOPE is switched 
off, HFIX restraints are switched on and ‘ANIS’ is inserted per default. These 
settings can be changed if desired. 
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5.1.9 Second and following shelxl runs 
All following shelxl runs should be started with the script shelxl2ff.py. This 
script skips the file copying from cns performed in shelxl1.py, and instead 
changes the file name of the already existing hkl file corresponding to the 
new refinement cycle. In addition, all steps of the script cleanup_pdb.py, 
which is also seperately available (chapter 5.1.11, p. 128), are performed. 
Chain IDs (generated by coot e.g. upon molecule merging or sorting) are 
deleted, ligands and glycerols are sorted before the water molecules (the 
coot 'merge molecules' function usually appends glycerols to the end of the 
pdb file and thus after already refined water molecules). Water molecules 
suggested by the previous shelxl run exhibit ‘W’ as atom names, which are 
not considered by the subsequent shelxpro generated .ins file if not 
changed to ‘O’. All water molecules have to be checked during coot 
refinement and deleted, if required. The remaining ‘W’-water molecules will 
be changed to ‘O’, and thus be considered and refined in the next cycle. The 
remaining steps are performed analogously to shelxl1.py. 
It has to be noted, that the pdb file from which the shelxl input file for the 
subsequent refinement cycles is generated, is always chosen by the user (per 
default, a pdb file with the ending -coot-0.pdb of the previous refinement 
cycle is selected by the script). Thus, if e.g. several variants starting from the 
same pdb file are tested during refinement, also pdb files from a refinement 
cycle before the previous one can be selected for continuation. The 
numbering of the refinement cycles will not be affected, but it is possible to 
add comments concerning the refinement procedure to the summary file at 
the right end of the lines, without disturbing the architecture of the tables. 
Such comments will be kept but not considered by the toolkit. 
A respective shelxh2ff.py script is available as well. 
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5.1.10 Utilising the toolkit after a manual refinement 
In addition, there are also two scripts provided, allowing the extraction of 
data processing and shelx refinement information of a refinement that had 
been performed manually before, or is even finished (read_all_infos_of_ 
finished_refinements.py). A subsequent use of the toolkit is facilitated by 
shelxl2ff_after_manual_refinement.py.  
First, for the use of read_all_infos_of_finished_refinements.py, it has to be 
assured, that for each .ins file .log and .lst files with corresponding names 
are available. If not, these .ins files have to be renamed (such as .ins_). The 
script will not consider them. Besides, a protein sequence file has to be 
provided in dataset/refine/info/ (see also chapter 5.1.4, p. 121). read_all_ 
infos_of_finished_refinements.py writes all information to a summary file in 
dataset/refine/shelxl/info.txt as already described above (chapter 5.1.8, 
p. 124) and .lig, .ala, .gap and .dbl files are generated for the 
corresponding refinement cycles. The sequence of refinement cycles is not 
obtained from the .ins file names but from the date and time on which the 
files had been generated. 
If, subsequently, refinement is continued utilising the toolkit, the summary 
file has to be copied to dataset/refine/info/. Afterwards, the first shelxl run 
has to be started with the script shelxl2ff_after_manual_refinement.py. This 
script is able to accept pdb files with arbitrary file names. Furthermore, the 
user can specify the starting number of the subsequent refinement cycle (e.g. 
06-prot-lig.ins), to keep the overall numbering consistent. 
All following shelxl runs should be started with the script shelxl2ff.py 
(chapter 5.1.9, p. 126). 
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5.1.11 Additional scripts 
analize_pdb.py - Counts number of protein atoms (considering atom 
occupancies of double conformations), water molecules, 
glycerol atoms and ligand atoms. 
- Calculates mean B-values of protein atoms, water 
molecules, glycerol atoms and ligand atoms. 
- Values are directly displayed within the shell and can 
be used for crystallographic tables in publications. 
cleanup_folder.py - Deletes all disc space consuming map files except the 
newest (fcf files are never deleted). 
- Deletes all intermediate coot-pdb-files (such as 01-
prot-log-coot-5.pdb) except the newest. 
- Deletes all session files and folders generated by coot. 
- gzips all files within the present folder. 
cleanup_pdb.py  - Deletes chain IDs within a pdb file generated by coot 
e.g. upon molecule merging or sorting. 
- Sorts ligands and glycerols before water molecules 
(the coot 'merge molecules' function usually appends 
glycerols to the end of the pdb file and thus after 
already refined water molecules). 
- Renames water molecule atom names from ‘W’ 
(suggested water molecules by shelxl) to ‘O’. 
make_dir.py - Generates the refine folder and its subfolders which 
are required by the toolkit. 




5.1.12 Template files provided by the toolkit 
bindividual.inp cns input file. 
default.txt see chapter 5.1.2, p. 120. 
generate.inp cns input file. 
GOL.dfx shelx restraint file for glycerol molecules. 
info-leer.txt empty info.txt file, may be edited in the first three lines 
and stored as dataset/refine/info/info.txt before the 
first run of the toolkit. In this case inserted values are 
read in automatically by the script and the user is not 
asked during the usage of cns1.py (chapter 5.1.6, 
p. 121). 
make_cv.inp cns input file. 
minimize.inp cns input file. 
model_map.inp cns input file. 
refine.inp cns input file. 
rigid.inp cns input file. 
tgt.seq excample file, containing the (entire) one letter amino 
acid sequence of tRNA guanine transglycosylase (TGT). 
water_pick.inp cns input file. 
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5.2 Multiple Sequence alignments 
Amino acid residues are coloured by their properties, according to the 
Clustal W colour code: red - hydrophobic, blue – acidic, magenta – basic, 
green – hydrophilic. consensus symbols: * - residue identical in all sequences 
in the alignment, : - conserved substitutions, . - semi-conserved 
substitutions. 
5.2.1 Multiple sequence alignment of human TGT with selected 
bacterial TGT structures 
ClustalW 1.83 [6] multiple sequence alignment of human TGT (hTGT) with selected 
bacterial TGT structures as template for homology modelling. Three wild-type 
Zymomonas mobilis TGT structures (PDB codes: 1r5y, 1y5v, 1y5w - resolutions: 1.20 Å 
and 1.58 Å, respectively), two Y106F variant structures (PDB codes: 1ozm, 1ozq - 
resolutions: 1.95 Å and 1.90 Å, respectively), and one structure of a covalent TGT-tRNA 
intermediate (PDB code: 1q2r (chain A and B) – resolution: 2.90 Å) were chosen. 
1R5Y.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1Y5W.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1Q2R.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1Y5V.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1Q2R.pdb_B      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1OZQ.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
1OZM.pdb_A      RPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVKALKPETVRATGADIILGN 60 
hTGT             ---MRLVAECSRSRARAGELWLPHGTVATPVFMPVGTQATMKGITTEQLDALGCRICLGN 57 
                         :      .:** * : : :*.: **.****** *::* :... :   *. * *.* 
 
1R5Y.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQVM--LSLTKQSEEGVTF------ 112 
1Y5W.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQV------TKQSEEGVTF------ 108 
1Q2R.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQVMSLSSLTKQSEEGVTFKSHLDG 120 
1Y5V.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQVM-----TKQSEEGVTFK----- 110 
1Q2R.pdb_B      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQVMSLSSLTKQSEEGVTFKSHLDG 120 
1OZQ.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGFQVMSLSSLTKQSEEGVTFKSHLDG 120 
1OZM.pdb_A      TYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGFQVMSLSSLTKQSEEGVTFKSHLDG 120 
hTGT             TYHLGLRPGPELIQKANGLHGFMNWPHNLLTDSGGFQMVSLVSLSEVTEEGVRFRSPYDG 117 
                  *:** *:** * *    ***.**.* : :******:*:       .  :*** *       
 
1R5Y.pdb_A      ---MLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 169 
1Y5W.pdb_A      ---MLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 165 
1Q2R.pdb_A      SRHMLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 180 
1Y5V.pdb_A      --HMLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 168 
1Q2R.pdb_B      SRHMLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 180 
1OZQ.pdb_A      SRHMLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 180 
1OZM.pdb_A      SRHMLSPERSIEIQHLLGSDIVMAFDECTPYPATPSRAASSMERSMRWAKRSRDAFDSRK 180 
hTGT             NETLLSPEKSVQIQNALGSDIIMQLDDVVSSTVTGPRVEEAMYRSIRWLDRCIAAHQR-- 175 




1R5Y.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 229 
1Y5W.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 225 
1Q2R.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 240 
1Y5V.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 228 
1Q2R.pdb_B      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 240 
1OZQ.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 240 
1OZM.pdb_A      EQAENAALFGIQQGSVFENLRQQSADALAEIGFDGYAVGGLAVGEGQDEMFRVLDFSVPM 240 
hTGT             --PDKQNLFAIIQGGLDADLRATCLEEMTKRDVPGFAIGGLSGGESKSQFWRMVALSTSR 233 
                      ::  **.* **.:  :**  .   ::. .. *:*:***: ** :.   .:  .:.   
 
1R5Y.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 289 
1Y5W.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 285 
1Q2R.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 300 
1Y5V.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 288 
1Q2R.pdb_B      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 300 
1OZQ.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 300 
1OZM.pdb_A      LPDDKPHYLMGVGKPDDIVGAVERGIDMFDCVLPTRSGRNGQAFTWDGPINIRNARFSED 300 
hTGT             LPKDKPRYLMGVGYATDLVVCVALGCDMFDCVFPTRTARFGSALVPTGNLQLRKKVFEKD 293 
                   **.***:*:** * .  ::  *  * ******:*** .* * *:.  * ::::    ... 
 
1R5Y.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 349 
1Y5W.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 345 
1Q2R.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 360 
1Y5V.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 348 
1Q2R.pdb_B      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 360 
1OZQ.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 360 
1OZM.pdb_A      LKPLDSECHCAVCQKWSRAYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRF 360 
hTGT             FGPIDPECTCPTCQKHSRAFLHALLHSDNTAALHHLTVHNIAYQLQLMSAVRTSIVEKRF 353 
                   : *:* .* * .*:: :*:::* *:  .:  .   :* *** :  .**. :* ** .  * 
 
1R5Y.pdb_A      SQFAQDFRARYF---------------------- 361 
1Y5W.pdb_A      SQFAQDFRARYF---------------------- 357 
1Q2R.pdb_A      SQFAQDFRARYFARNS------------------ 376 
1Y5V.pdb_A      SQFAQDFRARYF---------------------- 360 
1Q2R.pdb_B      SQFAQDFRARYF---------------------- 372 
1OZQ.pdb_A      SQFAQDFRARYF---------------------- 372 
1OZM.pdb_A      SQFAQDFRARYF---------------------- 372 
hTGT             PDFVRDFMGAMYGDPTLCPTWATDALASVGITLG 387 

































































































































































































































































































































































































































































































































































































Z. mobilis / H. sapiens # 
D102 / D89 
S103 / S90 
Y106 / F93 
D156 / D143 
C158 / V145 
Y161 / S148 
I201 / I184 
Q203 / Q186 
G229 / G212 
G230 / G213 
L231 / L214 
A232 / S215 
V233 / G216 
M260 / M243 
G261 / G244 
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5.2.3 Multiple sequence alignment of IpaA and IpgE homologues 
a) IpaA sequence (line 3) aligned with fragments of Salmonella typhimurium SipA (amino 
acids 48 - 264) from PDB codes 2fm9, chain A (line 1) and 2fm8, chain C (line 2). 
2FM9_A          ------------------------------------------------PQLEDFPALIKQ 12 
2FM8_C          ----------------------QATNLAANLSAVRESATATLSGEIKGPQLEDFPALIKQ 38 
IpaA            MHNVNNTQAPTFLYKATSPSSTEYSELKSKISDIHSSQTS-LKTPASVSEKENFATSFNQ 59 
                                                                .: *:*.: ::* 
 
2FM9_A          ASLDALFKCGKDAEALKEVFTNSNNVAGKKAIMEFAGLFRSALNATSDSPEAKTLLMKVG 72 
2FM8_C          ASLDALFKCGKDAEALKEVFTNSNNVAGKKAIMEFAGLFRSALNATSDSPEAKTLLMKVG 98 
IpaA            KCLDFLFSSSGKEDVLRSIYSNSMNAYAKSEILEFSNVLYSLVHQNGLNFENEKGLQKIV 119 
                 .** **... . :.*:.:::** *. .*. *:**:.:: * :: .. . * :. * *:  
 
2FM9_A          AEYTAQIIKDGLKEKSAFGPWLPETKKAEAKLENLEKQLLDIIKNNTGGELSKLSTNLVM 132 
2FM8_C          AEYTAQIIKDGLKEKSAFGPWLPETKKAEAKLENLEKQLLDIIKNNTGGELSKLSTNLVM 158 
IpaA            AQYSELIIKDKLSQDSAFGPWSAKNKKLHQLRQNIEHRLALLAQQHTSGEALSLGQKLLN 179 
                *:*:  **** *.:.****** .:.** .   :*:*::*  : :::*.**  .*. :*:  
 
2FM9_A          QEVMPYIASCIEHNFGCTLDPLTRSNLTHLVDKAAAKAVEALDMCHQKLTQEQGTSVGRE 192 
2FM8_C          QEVMPYIASCIEHNFGCTLDPLTRSNLTHLVDKAAAKAVEALDMCHQKLTQEQGTSVGRE 218 
IpaA            TEVSSFIKNNILAELKLSNETVSSLKLDDLVDAQAKLAFDSLRNQRKNTIDSKGFGIGKL 239 
                 ** .:* . *  ::  : :.::  :* .***  *  *.::*   :::  :.:* .:*:  
 
2FM9_A          ARHLEMQTLIPLLLRNVFAQIPA------------------------------------- 215 
2FM8_C          ARHLEMQTLIPLLLRNVFAQIP-------------------------------------- 240 
IpaA            SRDLNTVAVFPELLRKVLNDILEDIKDSHPIQDGLPTPPEDMPDGGPTPGANEKTSQPVI 299 
                :*.*:  :::* ***:*: :*                                        
 
b) IpgE sequence (line 3) aligned with the Salmonella enterica TTS chaperone SigE from 
PDB codes 1k3s, chain A (line 1) and chain B (line 2). 
1K3S_A          MESLLNRLYDALG-----LDEPLLIIDDGIQVYFNESDHTLEMCCPFMPLPDDILTLQHF 55 
1K3S_B          -ESLLNRLYDALG-----LDAPLLIIDDGIQVYFNESDHTLEMCCPFMPLPDDILTLQHF 54 
IpgE            MEDLADVICRALGIPLIDIDDQAIMLDDDVLIYIEKEGDSINLLCPFCALPENINDLIYA 60 
                 *.* : :  ***     :*   :::**.: :*:::...:::: *** .**::*  * :  
 
1K3S_A          LRLNYTSAVTIGADADNTALVALYRLPQTSTEEEALTGFELFISNVKQLKEHYA------ 109 
1K3S_B          LRLNYTSAVTIGADADNTALVALYRLPQTSTEEEALTGFELFISNVKQLKEH-------- 106 
IpgE            LSLNYSEKICLATDDEGGNLIARLDLTGINEFEDVYVNTEYYISRVRWLKDEFARRMKGY 120 




5.3 Kinetic measurements 
5.3.1 [8-3H ]-guanine TGT assay 
a) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 





b) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 
Cys158Val TGT variant for [8-3H ]-guanine and tRNATyr. 
  
  
c) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 





d) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 





e) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 
Cys158Val /Ala232Ser /Val233Gly TGT variant for [8-3H ]-guanine and tRNATyr. 
  
  
f) Initial velocities plotted against time, Lineweaver/Burk diagramm of wild-type TGT 




5.3.2 [8-3H ]-guanine-tRNATyr TGT 'washout assay' 
a) Initial velocities plotted against time, Michaelis Menten curve of wild-type TGT and 
preQ1. 
  
b) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 
Val233Gly TGT variant and preQ1. 
  
c) Initial velocities plotted against time, Michaelis Menten curve of Tyr106Phe / 




d) Initial velocities of Tyr106Phe / 
Cys158Val /Val233Gly TGT variant and 
preQ1 plotted against time. 
e) Initial velocities plotted against time, 
Michaelis Menten curve of 
Tyr106Phe / Ala232Ser /Val233Gly TGT 
variant and preQ1. 
f) Excorporation of [8-3H ]-guanine 
from labelled tRNATyr in the 
presence of queuine and Boc-preQ1 
 
5.4 MALDI-TOF/MS analysis of RNA oligoAsp reaction products 




b) preQ1-modified RNA oligoAsp (produced by wild-type TGT, and 500 M preQ1). 
  
c) preQ1-modified RNA oligoAsp (produced by wild-type TGT, and 5 M preQ1). 
  




e) preQ1-modified RNA oligoAsp (produced by Tyr106Phe /Val233Gly TGT variant). 
  
f) preQ1-modified RNA oligoAsp (produced by Tyr106Phe /Cys158Val /Val233Gly TGT 
variant). 
  




h) Partially preQ1-modified RNA oligoAsp (produced by Tyr106Phe /Val233Gly TGT variant 
and queuine). 
  
i) Unmodified RNA oligoAsp (produced by Tyr106Phe /Cys158Val TGT variant and 
queuine). 
  
j) RNA oligoAsp (produced by wild-type k) RNA oligoAsp (produced by Tyr106Phe / 
TGT and Boc-preQ1).  Cys158Val TGT variant and Boc-preQ1). 
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l) RNA oligoAsp (produced by Tyr106Phe / m) RNA oligoAsp (produced by Tyr106Phe / 
Cys158Val /Val233Gly TGT and Boc-  Cys158Val /Ala232Ser /Val233Gly TGT  
preQ1).  variant and Boc-preQ1). 
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BIH 2-butyl-1H-imidazole-4,5-dicarboxylic acid hydrazide 
Boc t-butyloxycarbonyl 
Da Dalton 
ESI electrospray ionisation 
GSH glutathione (reduced form) 
GSSG glutathione disulphide (oxidised form) 
GST glutathione S transferase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His6 hexa histidine 
HPLC high pressure liquid chromatography 
hTGT human TGT 
ics intra/inter cellular spread 
ipa invasion plasmid encoded antigen 
ipg invasion plasmid gene 
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
M cell membranous epithelial cell 
MALDI Matrix-assisted laser desorption/ionisation 
mRNA messenger RNA 
MS mass spectrometry 
mxi membrane expression of invasion plasmid antigens 
NMR nuclear magnectic resonance 
osp outer Shigella protein 
PBS phosphate buffer saline 
PEG polyethylene glycole 





rho ras homolog gene family 
sig Salmonella invasion gene 
sip Salmonella invasion protein 
spa surface presentation of invasion plasmid antigens 
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TGT tRNA guanine transgylcosylase 
TOF time of flight 
Tris trishydroxymethylaminomethane 
tRNA transfer RNA 
TTS type III secreton 





Strukturelle Charakteriserung und Mutationsstudie von Shigella Patho-
genitätsfaktoren 
An der Bakterienruhr, verursacht durch Shigella-Bakterien, erkranken jährlich 
163 Mio. Menschen. Die Erreger dringen in die Colon-Epithelzellen des 
Wirtes ein, vermehren sich dort und infizieren weitere Epithelzellen. Durch 
diesen Prozess wird ein Großteil des Epithels zerstört. Die Fähigkeit der 
Shigellen zur Invasion ist auf einem Virulenzplasmid kodiert. Die Expression 
der sog. Invasin-Gene wird durch den Virulenzfaktor VirF kontrolliert. Die 
Translation der virF-mRNA ist von der Aktivität eines tRNA-modifizierenden 
Enzyms, der tRNA-Guanin-Transglycosylase (TGT), abhängig. TGT-
Defektmutanten von Shigellen sind kaum noch in der Lage, Wirtszellen zu 
penetrieren. 
Klonierung, Expression, Aufreinigung und Kristallisation von Invasinen 
Im ersten Teil der Arbeit wurden die Invasingene ipaA, spa15, ipgB2, ospD1, 
ipgE, die für den Shigella-Invasionsmechanismus an unterschiedlicher Stelle 
von Bedeutung sind, kloniert und durch E. coli in großen Mengen produziert, 
lagen jedoch im Falle von IpaA, OspD1, IpgB2 unlöslich in Form von Ein-
schlusskörpern („Inclusion Bodies“) vor. In anschließenden Arbeiten sollen die 
Pathogenitätsfaktoren aus den Einschlusskörpern in eine lösliche Form 
überführt, weiter aufgereinigt und kristallisiert werden. IpgE wurde als 
Glutathion-S-Transferase-Fusionsprotein erfolgreich in löslicher Form in 
E. coli überproduziert und mittels Affinitätschromatographie, sowie Größen-
ausschlusschromatographie gereinigt. Die Identität des Proteins wurde 
mittels Massenspektrometrie verifiziert. Durch ein breit angelegtes 
Kristallisationsscreening wurden Bedingungen identifiziert, die zur IpgE-
Kristallisation geeignet sind. Diese sollen in nachfolgenden Arbeiten für eine 




Mutagenesestudie zur Substrat-Spezifität und -Selektivität der TGT 
Im zweiten Teil der Arbeit wurden Mutagenesestudien an einem Target der 
Wirkstoffentwicklung gegen Shigella - der TGT - durchgeführt, um neue Er-
kenntnisse über Substrat-Spezifität und -Selektivität gewinnen zu können. 
Die TGTs, evolutionär sehr alte Enzyme, sind in allen drei Domänen des 
Lebens vertreten, unterscheiden sich allerdings in ihrer Substrat-Spezifität 
und -Selektivität. So katalysieren zwar alle drei Varianten eine 
Austauschreaktion, bei der eine Guaninbase in tRNAs durch eine modifizierte 
Base ersetzt wird. Die eingefügte modifizierte Base ist jedoch in den drei 
Domänen verschieden (Archae: preQ0; Bakterien: preQ1; Eukaryoten: Queuin). 
Interessanterweise können eukaryotische TGTs in vitro auch die beiden 
Substrate ihrer verwandten TGTs erkennen und in tRNAs inserieren, während 
ihre archaeaelle Variante außer dem eigenen Substrat nur Guanin in der 
Bindetasche aufnehmen kann. Die bakterielle TGT erkennt zwar ebenfalls das 
archaeaelle Substrat, kann aber das eukaryotische Substrat nicht umsetzen. 
Die unterschiedlichen Substratspezifitäten der archaeaellen und bakteriellen 
TGTs beruhen auf einem Peptidbindungsflip im aktiven Zentrum, der in 
Bakterien durch den Protonierungszustand von Glutamat235 kontrolliert wird. 
Der Peptidflip ändert die Eigenschaften der Bindetasche so, dass entweder 
Guanin oder preQ1 gebunden werden kann. Das Konformer, das Guanin 
erkennt, ist ebenfalls in der Lage, preQ0 zu binden. In Archaea kann die 
entsprechende Peptidbindung ihre Orientierung nicht ändern, da sie durch 
eine invariante Rückgratwechselwirkung stabilisiert wird. Für eine TGT(Glu235 
Gln)-Variante, die, ähnlich dem archaeaellen Enzym, eine bevorzugte 
Stabilisierung des Peptipflips in derjenigen Orientierung gewährleisten sollte, 
die das Binden von Guanin und preQ0 bevorzugt, konnte gezeigt werden, 
dass die Selektivität zugunsten von preQ0 umgekehrt wird. Zahlreiche 
Kristallstrukturen der mutierten TGT in Komplex mit den verschiedenen 
Substraten konnten belegen, dass die Bindetasche im mutierten Enzym 
tatsächlich hauptsächlich in der Konformation vorliegt, die das Binden von 
Guanin und preQ0 ermöglicht. 
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Die Substrat-Promiskuität des eukaryotischen Enzyms basiert auf der 
Tatsache, dass die Substratbindetasche sehr groß sein muss, um Queuin 
aufnehmen zu können. Die entscheidenden Interaktionen werden jedoch zu 
dem heterozyklischen, guaninähnlichen Teil des Moleküls ausgebildet, der in 
allen drei Substraten analog ist. So können auch die wesentlich kleineren, 
aber in diesem Bereich sehr ähnlichen Substrate preQ0 und preQ1 durch die 
eukaryotische TGT erkannt und umgesetzt werden. Im Vergleich eines 
Homologiemodells der humanen TGT mit einer Kristallstruktur der 
Zymomonas mobilis TGT wurden Aminosäuren in der Bindetasche iden-
tifiziert, die für eine Vergrößerung der Bindetasche in eukaryotischen TGTs 
verantwortlich sein könnten. Um die Unterschiede der bakteriellen und 
humanen TGT-Bindetaschen näher zu beleuchten, wurden Z. mobilis TGT-
Varianten konstruiert, bei denen diese Reste ausgetauscht wurden, um eine 
solch vergrößerte Bindetasche zu schaffen, und biochemisch sowie 
strukturell charakterisiert. Die erzeugten TGT-Varianten zeigten eine 
signifikante Erniedrigung ihrer Wechselzahlen. Es muss daher angenommen 
werden, dass die ausgetauschten Reste, trotz ihrer relativ großen Entfernung 
zum katalytischen Rest Asp280, einen entscheidenden Einfluss auf die 
katalytische Aktivität des Enzyms ausüben. In kinetischen Messungen wurde 
beobachtet, dass lediglich eine der TGT-Varianten TGT(Val233Gly), sowie 
unerwarteter Weise bereits das Z. mobilis Wildtyp-Enzym bei sehr hohen 
Queuin-Konzentrationen in der Lage sind, radioaktiv markiertes Guanin aus 
tRNA in Gegenwart von Queuin auszubauen. Analyse von Komplex-
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